

UNIFORM GUIDANCE REPORTS AND SCHEDULES

Nationwide Children's Hospital, Inc. and Subsidiaries
Year Ended December 31, 2019
With Report of Independent Auditors

Ernst & Young LLP



Nationwide Children’s Hospital, Inc. and Subsidiaries

Uniform Guidance Reports and Schedules

Year Ended December 31, 2019

Contents

Report of Independent Auditors.....1

Consolidated Financial Statements

Consolidated Balance Sheets3

Consolidated Statements of Operations and Changes in Net Assets5

Consolidated Statements of Cash Flows.....7

Notes to Consolidated Financial Statements.....8

Supplementary Information

Schedule of Expenditures of Federal Awards.....50

Notes to the Schedule of Expenditures of Federal Awards70

Compliance and Internal Controls

Report of Independent Auditors on Internal Control Over Financial Reporting and on
Compliance and Other Matters Based on an Audit of Financial Statements
Performed in Accordance with *Government Auditing Standards*71

Report of Independent Auditors on Compliance for the Major Federal Program and
Report on Internal Control over Compliance Required by the Uniform Guidance.....73

Schedule of Findings and Questioned Costs.....76



Ernst & Young LLP
Suite 200
800 Yard Street
Grandview Heights, OH 43212

Tel: +1 614 224 5678
Fax: +1 614 232 7939
ey.com

Report of Independent Auditors

Senior Management and Board of Directors
Nationwide Children's Hospital, Inc.

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Nationwide Children's Hospital, Inc. and Subsidiaries, which comprise the consolidated balance sheets as of December 31, 2019 and 2018, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Nationwide Children's Hospital, Inc. and Subsidiaries as of December 31, 2019 and 2018, and the consolidated results of their operations and their cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Changes in Accounting Principles


As discussed in Note 2 to the consolidated financial statements, in 2019 Nationwide Children's Hospital, Inc. and Subsidiaries changed their method for recognizing leases as a result of the adoption of Accounting Standards Update (ASU) 2016-02, *Leases (Topic 842)*. Our opinion is not modified with respect to this matter.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The Schedule of Expenditures of Federal Awards as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated April 23, 2020 on our consideration of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over financial reporting and compliance.



April 23, 2020, except for the schedule of expenditures of federal awards for which the date is June 12, 2020

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Balance Sheets

	December 31	
	2019	2018
	<i>(In Thousands)</i>	
Assets		
Current assets:		
Cash and cash equivalents	\$ 304,557	\$ 318,793
Restricted cash	37,838	15,975
Patient accounts receivable	307,800	273,491
Inventories	11,890	10,775
Pledges receivable (Note 14)	7,114	9,034
Other assets	97,781	158,332
Total current assets	<u>766,980</u>	<u>786,400</u>
Assets limited as to use (Note 5):		
Held by trustee	26,016	30,378
Board-designated:		
Capital improvement	66,866	58,996
Other	2,796,165	2,110,537
Donor restricted	335,841	300,013
Total assets limited as to use	<u>3,224,888</u>	<u>2,499,924</u>
Pledges receivable (Note 14)	20,909	25,929
Property and equipment, less allowance for depreciation (Note 13)	1,433,443	1,332,294
Other assets	70,967	31,618
Total assets	<u>\$ 5,517,187</u>	<u>\$ 4,676,165</u>

	December 31	
	2019	2018
	<i>(In Thousands)</i>	
Liabilities and net assets		
Current liabilities:		
Accounts payable and accrued expenses	\$ 80,628	\$ 77,584
Compensation and related taxes	142,717	127,891
Current portion of long-term debt <i>(Note 8)</i>	111,284	80,575
Accrued claims expense	71,728	147,914
Other current liabilities	27,245	30,797
Total current liabilities	<u>433,602</u>	<u>464,761</u>
Long-term liabilities:		
Retirement benefits	29,996	32,612
Long-term debt <i>(Note 8)</i>	689,496	567,120
Professional liability	26,000	30,367
Interest rate swaps <i>(Note 10)</i>	34,865	22,951
Other long-term liabilities	79,907	59,539
	<u>860,264</u>	<u>712,589</u>
Total liabilities	<u>1,293,866</u>	<u>1,177,350</u>
Net assets:		
Without donor restrictions	3,881,140	3,189,627
With donor restrictions <i>(Note 18)</i>	342,181	309,188
Total net assets	<u>4,223,321</u>	<u>3,498,815</u>
Total liabilities and net assets	<u>\$ 5,517,187</u>	<u>\$ 4,676,165</u>

See accompanying notes.

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Operations and Changes in Net Assets

	Year Ended December 31	
	2019	2018
	<i>(In Thousands)</i>	
Unrestricted revenue, gains, and other support		
Patient service revenue <i>(Note 4)</i>	\$ 1,469,682	\$ 1,375,315
Premium revenue	990,181	930,594
Other revenue	203,707	162,673
Net assets released from restrictions	32,556	35,862
Total unrestricted revenue, gains, and other support	<u>2,696,126</u>	<u>2,504,444</u>
Expenses		
Salaries and benefits	1,124,234	1,051,476
Claims expense	585,530	521,955
Supplies	308,813	253,314
Purchased services	138,921	124,802
Interest	21,409	21,344
Depreciation and amortization	94,913	94,579
Other	205,703	193,160
Total expenses	<u>2,479,523</u>	<u>2,260,630</u>
Operating income	216,603	243,814
Investment return – net <i>(Note 5)</i>	460,341	(144,230)
Other nonoperating gains – net <i>(Note 1)</i>	12,737	22,372
Excess of revenue over expenses	<u>689,681</u>	<u>121,956</u>

Continued on next page

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Operations and Changes in Net Assets (continued)

	Year Ended December 31	
	2019	2018
	<i>(In Thousands)</i>	
Net assets without donor restrictions		
Excess of revenue over expenses	\$ 689,681	\$ 121,956
Change in pension obligation and assets	1,732	(2,030)
Net assets released from restrictions for the purchase of property and equipment	100	—
Increase net assets without donor restrictions	<u>691,513</u>	119,926
Net assets with donor restrictions		
Contributions	39,771	40,661
Net assets released from restrictions for the purchase of property and equipment	(100)	—
Investment return, net	26,113	(7,707)
Net assets released from restrictions	(32,556)	(35,862)
Transfers and other	(235)	95
Increase (decrease) in net assets with donor restrictions	<u>32,993</u>	(2,813)
Increase in net assets	724,506	117,113
Net assets at beginning of year	<u>3,498,815</u>	<u>3,381,702</u>
Net assets at end of year	<u>\$ 4,223,321</u>	<u>\$ 3,498,815</u>

See accompanying notes.

Nationwide Children's Hospital, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

	Year Ended December 31	
	2019	2018
	<i>(In Thousands)</i>	
Operating activities		
Increase in net assets	\$ 724,506	\$ 117,113
Adjustments to reconcile increase in net assets to cash provided by operating activities:		
Net change in unrealized (gains) losses on investments	(365,880)	244,937
Change in fair value of interest rate swaps	27,321	(6,337)
Change in pension obligation and assets	(1,732)	2,030
Depreciation and amortization	94,772	94,579
Net changes in assets limited as to use	(359,084)	(202,965)
Restricted contributions and investment income	(44,819)	(45,865)
(Increase) decrease in:		
Patient accounts receivable	(34,309)	(35,994)
Inventories	(1,115)	(815)
Other current assets	60,551	(68,831)
Pledges receivable	6,940	1,710
Other long-term assets	(14,103)	(253)
Increase (decrease) in:		
Accounts payable and accrued expenses	3,044	8,177
Compensation and related taxes	14,826	8,768
Other current liabilities	(8,645)	(5,886)
Accrued claims expense	(76,186)	78,488
Retirement benefits	(884)	(4,011)
Professional liability	(4,367)	(831)
Other long-term liabilities	(1,353)	(952)
Net cash provided by operating activities	19,483	183,062
Investing activities		
Purchase of property and equipment	(194,376)	(195,778)
Net cash used in investing activities	(194,376)	(195,778)
Financing activities		
Proceeds from issuance of long-term debt	167,476	-
Swap termination payment	(15,407)	-
Debt issuance costs	(2,073)	-
Repayment of long-term debt	(12,295)	(13,675)
Restricted contributions and investment income	44,819	45,865
Net cash provided by financing activities	182,520	32,190
Net increase in cash, cash equivalents and restricted cash	7,627	19,474
Cash, cash equivalents, and restricted cash at beginning of year	334,768	315,294
Cash, cash equivalents, and restricted cash at end of year	\$ 342,395	\$ 334,768

See accompanying notes.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

Years Ended December 31, 2019 and 2018

1. Organization and Significant Accounting Policies

Nationwide Children's Hospital, Inc. (Nationwide Children's) exclusively controls the activities of its subsidiaries in Central Ohio, including:

- **Nationwide Children's Hospital** (the Hospital) is a 679-bed not-for-profit tertiary care hospital, providing inpatient, outpatient, and emergency care services. Included within the bed count, the Hospital leases 146 neonatal intensive and special care nursery beds located at six other area hospitals. Subsidiaries of the Hospital include the following entities:
 - **Children's Radiological Institute** (CRI) is a not-for-profit professional practice plan owned by the Hospital, which provides radiological services at the Hospital.
 - **Nationwide Children's Hospital Homecare** (Homecare Services) is a not-for-profit home health company owned by the Hospital, which provides intermittent and private-duty nursing, skilled therapy, infusion therapy, durable medical equipment, hospice, and palliative care services.
 - **Pediatric Pathology Associates of Columbus** (PPAC) is a not-for-profit professional practice plan owned by the Hospital, which provides pathological services at the Hospital.
 - **Children's Surgical Associates** (CSA) is a not-for-profit professional practice plan owned by the Hospital, which provides surgical services at the Hospital.
 - **Pediatric Academic Association** (PAA) is a not-for-profit practice of which the Hospital owns 51%. The PAA is a group of approximately 500 medical, pediatric subspecialists, which provides such services at the Hospital. The remaining 49% ownership interest held by The Ohio State University Clinical Practice Plan was transferred to the faculty members of the Department of Pediatrics of The Ohio State University College of Medicine. The non-controlling interest was \$8,000 and \$557,000 as of December 31, 2019 and 2018, respectively.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

- **Children's Anesthesia Associates, Inc. (CAA)** is a for-profit professional practice plan which provides anesthesiology services at the Hospital.
- **Pediatric Clinical Trials International, Inc. (PCTI)** is a for-profit site management organization (SMO) which provides pediatric pharmaceutical research and testing services. Currently, there is no activity within this company.
- **Nationwide Children's Hospital Foundation (Foundation)** is a not-for-profit charitable foundation.
- **The Research Institute at Nationwide Children's Hospital (Research Institute)** is a not-for-profit pediatric medical research institute.
- **Center for Child and Family Advocacy at Nationwide Children's Hospital (CCFA)** is a not-for-profit organization that provides advocacy, education, counseling and other programmatic services to children and families suffering from child abuse and neglect. CCFA also is known by its operating name – The Center for Safety and Family Healing.
- **Children's Hospital and Physicians Healthcare Network (d/b/a Partners for Kids)** is a joint venture between the Hospital and community physicians. Partners for Kids is a not-for-profit formed to contract with insurers offering Medicaid or commercial managed care products for the provision of medical services. As a result of the Hospital's affiliation with certain physician groups, the Hospital has effective control of the Partners for Kids board and an economic interest in Partners for Kids.

Basis of Presentation

The consolidated financial statements include the accounts of Nationwide Children's Hospital, Inc. and its subsidiaries, collectively referred to as Nationwide Children's or the Corporation. Significant interorganization accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Cash, Cash Equivalents, and Restricted Cash

Nationwide Children's defines cash as currency on hand and demand deposits with financial institutions. Cash equivalents are defined as short-term, highly liquid investments with remaining maturities of three months or less at the time of acquisition, excluding those held in assets limited as to use. The carrying amount of cash equivalents approximates fair value. Nationwide Children's had \$37,838,000 and \$15,975,000 of restricted cash deposited in escrow accounts related to Partners for Kids for claims liability funding at December 31, 2019 and 2018, respectively.

Investments

Investments in equity securities and mutual funds with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheets. Investment return (including interest and dividends, realized gains and losses on the sale of investments, and changes in unrealized gains and losses on investments) is included in the excess of revenue over expenses unless the income or loss is restricted by the donor or law.

Excess of Revenue Over Expenses

The consolidated statements of operations and changes in net assets include excess of revenue over expenses as the performance indicator. Changes in net assets, which are excluded from excess of revenue over expenses, consistent with industry practice, include contributions of long-lived assets (including assets acquired using contributions, which by donor restriction were to be used for the purposes of acquiring such assets), transfers and the change in pension obligations and assets.

Patient Accounts Receivable and Patient Service Revenue

Patient service revenue and patient accounts receivable are reported at the amount that reflects the consideration to which Nationwide Children's expects to be entitled in exchange for providing patient care.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Premium Revenue and Associated Costs

Premium revenue represents revenue derived under capitated arrangements between Partners for Kids and third parties. In return for these premiums, Partners for Kids is responsible for providing essentially all health care services to enrolled participants. Premium revenue is recognized as Partners for Kids satisfies its performance obligations over time. Costs for providing these services, including services provided by other health care providers, are included in operating expenses in the consolidated financial statements.

As the actuarially determined accrual for incurred but not reported claims is an estimate (based upon a historical claims lag method), the possibility exists that the estimate could be revised by a material amount in the near term. Partners for Kids maintains stop-loss insurance coverage to limit exposure for certain catastrophic claims. The policy limit is \$1,000,000 per year per claim.

Inventories

Inventories, consisting of drugs, medical and surgical supplies, are valued at the lower of cost, determined on a first-in, first-out basis, or market.

Property and Equipment

Property and equipment are stated at cost or at estimated fair value if acquired by gift. Depreciation of property and equipment is provided on the straight-line method at rates based on the estimated useful lives of the assets.

Bond Issuance Costs

Nationwide Children's records certain costs associated with the issuance of its bonds and reports these costs as a reduction in the related debt. The costs are amortized over the life of the bonds using a method that approximates the effective interest method.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Derivatives

Nationwide Children's uses interest rate swaps as part of its overall debt management policy. Nationwide Children's accounts for interest rate swaps in accordance with Accounting Standards Codification (ASC) 815, *Derivatives and Hedging*, which requires that all derivatives be carried at fair value in the consolidated balance sheets. The related changes in fair value are reported in the consolidated statements of operations and changes in net assets as a component of excess of revenue over expenses.

Fair Value

A financial instrument's categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value assessments are made at a specific point in time based on relevant market information about the financial instrument. See Note 6 for a description of the fair value hierarchy.

Community Benefits and Charity Care

Nationwide Children's provides programs and services to address the needs of those in the community with limited financial resources, generally at no or low cost to those being served. Additional services are provided to beneficiaries of governmental programs (principally those relating to the Medicare and Medicaid programs) at substantial discounts from established rates and are considered part of Nationwide Children's benefit to the community.

Assistance also is provided as needed to patients and their families for the submission of forms for insurance, financial counseling, and application to the Medicare and Medicaid programs for health service coverage. In addition, interpretive services are provided to those families who either cannot or have difficulty speaking English. The costs of providing these programs and services are included in expenses.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

Consistent with Nationwide Children’s mission, care is provided to patients regardless of their ability to pay. Patients who meet certain criteria for charity care are provided care without charge or at amounts less than established rates. Because collection of amounts determined to qualify as charity care is not pursued, such amounts are not reported as patient service revenue. Records are maintained to identify and monitor the level of charity care provided, including the amount of charges foregone for services and supplies furnished. The amount of charges forgone for services and supplies furnished under Nationwide Children’s charity care policies follows for the years ended December 31:

	<u>2019</u>	<u>2018</u>
Charges, foregone, based on established rates	\$ 57,716	\$ 45,161
Management’s estimate of costs incurred to provide charity care	\$ 24,010	\$ 18,064
Equivalent percentage of cost of charity care services to gross patient service revenue, based on established rates	<u>41.6%</u>	<u>40.0%</u>

Estimates of costs incurred to provide charity care are based upon historical amounts derived from Medicaid cost reports.

Operating and Nonoperating Activities

Nationwide Children’s principal activity is the provision of diversified health care services to the community. As such, activities related to the ongoing operations of Nationwide Children’s are classified as revenue. Other revenue includes those generated from patient care related support services, research, certain donated revenue and sundry revenue related to the operation of Nationwide Children’s. Gains and losses not directly related to the ongoing operations of Nationwide Children’s or that occur infrequently are reported as nonoperating gains and losses. Included in nonoperating gains and losses are unrestricted contributions, changes in fair value of interest rate swaps, interest rate swap termination costs, extinguishment of debt, revenue and costs associated with technology commercialization investments, and gains on the sale of property and equipment.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

1. Organization and Significant Accounting Policies (continued)

The following table sets forth other non-operating gains – net for the years ended December 31:

	2019	2018
	<i>(In Thousands)</i>	
Unrestricted contributions	\$ 13,127	\$ 7,999
Change in fair value of interest rate swaps	(11,914)	6,337
Technology investments	27,694	7,080
Distribution obligation	(6,873)	(2,603)
Swap termination payment	(15,407)	–
Other	6,110	3,559
Other nonoperating gains – net	\$ 12,737	\$ 22,372

Federal Income Taxes

Nationwide Children’s is incorporated under the laws of the State of Ohio. Nationwide Children’s and its subsidiaries, except PCTI, CAA, and NCH Realty, Inc., are tax-exempt organizations as defined under Section 501(c)(3) of the Internal Revenue Code. Income taxes on the for-profit subsidiaries, PCTI, CAA, and NCH Realty, Inc., are not significant.

Nationwide Children’s records accruals for uncertain tax positions under ASC 740, *Income Taxes*. Nationwide Children’s had no significant uncertain tax positions as of December 31, 2019 and 2018.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

2. Pending and Newly Adopted Accounting Guidance

Effective January 1, 2019, Nationwide Children’s adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-02, *Leases (Topic 842)* using the modified retrospective method of transition. The guidance in ASU 2016-02 supersedes the lease accounting requirements in ASC Topic 840, *Leases*, which required only finance leases to be recognized on

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Pending and Newly Adopted Accounting Guidance (continued)

the balance sheet. ASU 2016-02 requires the rights and obligations arising from the lease contracts, including existing and new arrangements, to be recognized as assets and liabilities on the balance sheet. Additionally, the ASU requires qualitative and quantitative disclosures, included in Note 9, to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The adoption of ASU 2016-02 constitutes a change in accounting principle under ASC 250, *Accounting Changes and Error Corrections*. The primary effect of adopting the ASU was to record right-of-use assets and obligations for current operating leases. The impact of adoption on the consolidated financial statements resulted in an increase in other noncurrent assets to record right-of-use assets of \$29.1 million, and an increase in other current and noncurrent liabilities of \$5.0 million and \$25.6 million, respectively, to record remaining lease payments for operating leases. The impact of the adoption of ASU 2016-02 did not have a material impact on excess of revenues over expenses or net assets to its consolidated financial statements.

Effective January 1, 2019, Nationwide Children's adopted ASU 2016-18, *Restricted Cash*, which requires entities to show the changes in the total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. Nationwide Children's reports cash, cash equivalents, restricted cash and restricted cash equivalents in more than one line on the consolidated balance sheet. Nationwide Children's adopted the ASU on a retrospective basis and has adjusted the presentation in these consolidated financial statements accordingly.

In August 2018, the FASB issued ASU 2018-13, *Fair Value Measurement, Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement*. ASU 2018-13 intends to improve the effectiveness of disclosures in the notes to financial statements by modifying disclosure requirements for fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. Nationwide Children's is evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

In August 2018, the FASB issued ASU 2018-14, *Compensation – Retirement Benefits – Defined Benefit Plans – General, Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans*. ASU 2018-14 intends to improve the effectiveness of disclosures in the notes to the financial statements by modifying disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. ASU 2018-14 is effective for fiscal years beginning after December 15, 2021, with early adoption permitted. Nationwide Children's is evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

2. Pending and Newly Adopted Accounting Guidance (continued)

In August 2018 the FASB issued ASU 2018-15, *Intangibles – Goodwill and Other – Internal-Use Software, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract*. ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. ASU 2018-15 is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. Nationwide Children's is evaluating the impact that this standard will have on its consolidated financial statements and will adopt the provisions upon the effective date.

3. Third-Party Settlements

Estimated third-party settlements for various programs (Bureau of Children with Medical Handicaps, Medicare and Medicaid) reflect differences between interim reimbursement and reimbursement as determined by reports filed after the end of each year. In addition, such third-party settlements reflect, if applicable, any differences found to be owed to or by the Hospital after government agencies have audited these reports. The Hospital has received interim payments under Title V (Bureau of Children with Medical Handicaps) and Title XIX (Medicaid) programs but has not yet received final settlement for the years 2013 through 2019. Final settlement of amounts is subject to audit and verification by the appropriate governmental agency. The amounts reported in the consolidated financial statements represent the estimated settlements outstanding, which the Hospital's management believes will approximate final settlements.

Revenue from the Medicaid program accounted for 16% and 17% of the Hospital's net patient service revenue for the years ended December 31, 2019 and 2018, respectively. Laws and regulations governing the Medicaid program are complex and subject to interpretation. The Hospital believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicaid program. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue

Nationwide Children's provides health care services through inpatient, outpatient, and ambulatory care facilities. Patient care service revenue is reported at the amount that reflects the consideration to which Nationwide Children's expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, Nationwide Children's bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by Nationwide Children's. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Nationwide Children's believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the hospital receiving inpatient acute care services. Nationwide Children's measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and Nationwide Children's does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, Nationwide Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Nationwide Children's uses a portfolio approach to account for categories of patient contracts as a collective group, rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes for inpatient revenue and outpatient revenue. Based on the historical collection trends and other analysis, Nationwide Children's believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue (continued)

Nationwide Children's determines the transaction price based on standard charges for goods and services provided, reduced by explicit price concessions provided to third-party payors, discounts provided to uninsured patients in accordance with Nationwide Children's policy, and/or implicit price concessions provided to uninsured patients. Nationwide Children's determines its estimates of explicit price concessions based on contractual agreements, its discount policy, and historical experience. Nationwide Children's determines its estimate of implicit price concessions based on its historical collection experience with each class of patients.

Revenue from third-party payors is subject to retroactive adjustments due to audits, reviews, changes in program administration and rules, and outcome of litigation. These settlements are estimated based on the agreement with the payor and correspondence, which includes an assessment to ensure it is probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associated with the retroactive adjustments is subsequently resolved.

Agreements with third-party payors typically provide for payments at amounts less than established charges. The following is a summary of the payment arrangements with major third-party payors:

Commercial: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.

The Ohio Department of Medicaid administers a federally sponsored program, which provides additional reimbursement to hospitals that serve a disproportionate share of indigent patients (Care Assurance Program). The current program allocation formula generally is based on individual hospitals' components of indigent care in relation to statewide totals. Future funding of the Care Assurance Program is contingent on annual governmental approval, and the program's long-term existence is uncertain.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue (continued)

For the years ended December 31, 2019 and 2018, revenue recognized related to this program was recorded within patient service revenue in the consolidated statements of operations and changes in net assets, totaling \$33,742,000 and \$52,345,000, with offsetting HCAP assessments of \$7,168,000 and \$6,733,000, respectively. Nationwide Children’s has recorded a liability of \$57,394,000 in other long-term liabilities in the consolidated balance sheets as of December 31, 2019 and 2018, related to this program. Of this amount, \$30,676,000 relates to 2015 and \$26,718,000 relates to 2014, based on information provided by the Ohio Department of Medicaid during 2015.

Self Pay: Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. Nationwide Children’s also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. Nationwide Children’s estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. For the years ended December 31, 2019 and 2018, the changes to the estimates of implicit price concessions for performance obligations satisfied in prior years were not significant. Subsequent changes that are determined to be the result of an adverse change in the patient’s ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2019 and 2018, was \$480,000 and \$380,000, respectively.

Other: Payment agreements with certain governmental insurance carriers, government agencies, and non-government organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Patient revenue by major payor source, net of price concessions, for the year ended December 31 are as follows:

	2019	2018
	<i>(In Thousands)</i>	
Commercial	\$ 1,187,699	\$ 1,107,942
Medicaid	242,268	238,907
Self-pay	8,815	9,669
Other	30,900	18,797
	<u>\$ 1,469,682</u>	<u>\$ 1,375,315</u>

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

4. Patient Service Revenue (continued)

Nationwide Children’s has elected the practical expedient allowed under FASB ASC 606-10-32-18 and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component, due to Nationwide Children’s expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, Nationwide Children’s does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

5. Assets Limited as to Use

The composition of assets limited as to use recorded value at December 31 is set forth in the following table:

	December 31	
	2019	2018
	<i>(In Thousands)</i>	
Trustee funds:		
Cash equivalents	\$ 3,387	\$ 4,852
Fixed income:		
Mutual funds	10,290	11,248
Equities – mutual funds:		
Domestic large-cap indexed	5,516	6,538
Domestic mid-cap indexed	914	1,071
Domestic small-cap	1,458	1,653
International	3,315	3,697
Commodities fund	1,136	1,319
	26,016	30,378

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Assets Limited as to Use (continued)

	December 31	
	2019	2018
Board-designated capital improvement:		
Cash equivalents	\$ 327	\$ 197
Fixed income:		
U.S. Treasury notes	12,805	11,881
U.S. Government agencies	1,459	3,493
Corporate obligations	18,055	12,538
Foreign obligations	708	1,251
Mutual funds	6,160	5,313
Equities – mutual funds:		
Domestic large-cap indexed	10,494	8,468
Domestic mid-cap indexed	1,740	1,328
Domestic small-cap	1,393	1,088
International	6,063	4,933
Equity securities:		
Domestic small-cap	1,421	1,124
Commodities fund	2,881	2,744
Private equity	3,360	4,638
	66,866	58,996
Board-designated other:		
Cash equivalents	198,764	98,624
Fixed income:		
U.S. Treasury bonds	28,256	20,691
U.S. Treasury notes	64,645	43,916
U.S. Government agencies	35,754	63,103
Corporate obligations	210,643	147,172
Foreign obligations	26,799	24,610
Mutual funds	279,840	201,828
Equities – mutual funds:		
Domestic large-cap indexed	846,018	662,801
Domestic mid-cap indexed	135,653	101,707
Domestic small-cap	108,231	81,037
International	473,293	359,068
Equity securities:		
Domestic small-cap	111,759	83,673
Commodities fund	105,207	94,897
Private equity and private credit	171,303	127,410
	2,796,165	2,110,537

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Assets Limited as to Use (continued)

	December 31	
	2019	2018
Donor restricted:		
Cash equivalents	\$ 42,893	\$ 18,210
Fixed income:		
U.S. Treasury bonds	2,545	2,364
U.S. Treasury notes	19,861	19,196
U.S. Government agencies	4,804	11,378
Corporate obligations	38,781	31,778
Foreign obligations	3,192	4,306
Mutual funds	28,584	25,642
Equities – mutual funds:		
Domestic large-cap indexed	84,151	85,283
Domestic mid-cap indexed	13,995	13,014
Domestic small-cap	11,429	10,401
International	52,717	45,539
Equity securities:		
Domestic small-cap	11,594	10,703
Commodities fund	12,644	14,183
Private equity	7,845	7,575
Other	806	441
	335,841	300,013
Total assets limited as to use	\$ 3,224,888	\$ 2,499,924

Nationwide Children’s has committed capital yet to be called of approximately \$99,101,000 at December 31, 2019, to private equity and private credit funds over the next four to six years.

As of December 31, 2019 and 2018, assets limited as to use included an investment in a mutual fund equaling approximately 30% of the consolidated investment balance. This passively managed fund is indexed to the S&P 500; therefore, management believes no concentration of credit risk exists with regard to this investment.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

5. Assets Limited as to Use (continued)

The composition of the investment return on board designated and funds held by trustee recognized in the consolidated statements of operations and changes in net assets is as follows for the year ended December 31:

	<u>2019</u>	<u>2018</u>
	<i>(In Thousands)</i>	
Investment return – net:		
Dividend and interest income	\$ 60,722	\$ 47,072
Realized gains on the sale of investments, net	54,804	40,725
Unrealized gains (losses) on investments, net	344,815	(232,027)
	<u>\$ 460,341</u>	<u>\$ (144,230)</u>

6. Fair Value Measurements

Below is the fair value hierarchy that categorizes into three levels the inputs to valuation techniques that are used to measure fair value:

- Level 1 includes observable inputs that reflect quoted prices for identical assets or liabilities in active markets at the measurement date.
- Level 2 includes observable inputs for assets or liabilities other than quoted prices included in Level 1, and valuation techniques that use prices for similar assets and liabilities.
- Level 3 includes unobservable inputs that reflect the reporting entity’s estimates of the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).

Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.

Cash and cash equivalents principally are invested in money market funds. The money market funds are valued at their net asset value. Net asset value is equal to the fair value of each money market fund’s investments and other assets, less liabilities, divided by the number of fund shares.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

The money market funds are comprised of highly liquid investments with maturities of three months or less at date of acquisition and are classified as Level 1 instruments. Equity securities and mutual funds are valued at the closing price on the exchange where the security principally is traded, a market-based valuation technique. The instruments are classified as Level 1, because quoted prices in active markets are available. Nationwide Children's does not adjust quoted prices for such instruments.

U.S. Treasury bonds, U.S. Treasury notes, U.S. Government agencies, and corporate obligations are valued based upon a compilation of primarily observable market information or quoted prices that are not active. Foreign obligations are valued using vendor-evaluated prices. Because the evaluated prices for these fixed-income securities are based upon observable inputs, such as available trade information, spreads, bids and offers, broker feeds and reported trades, adjustments for corporate actions, and benchmark yields, instruments in these categories are classified as Level 2 securities. For interest rate swap liabilities, the Corporation uses a discounted cash flow analysis, incorporating interest rates and London Interbank Offered Rate (LIBOR) curves when assessing fair value, an income-based valuation technique. Such instruments generally are classified as Level 2 securities. The commodities fund, private equity and private credit investments are accounted for using the equity method of accounting. These investments (commodities fund of \$121,868,000 and \$113,143,000 at December 31, 2019 and 2018, respectively, and private equity and private credit totaling \$182,508,000 and \$139,623,000 at December 31, 2019 and 2018, respectively) are not required to be marked to fair value on a recurring basis and, therefore, are not included in the accompanying tables. The carrying values of these investments are based on valuations provided by the administrators of the specific financial instruments. The underlying investments in these financial instruments may include marketable debt and equity securities, commodities, foreign currencies, derivatives, and private equity investments. The underlying investments are subject to various risks, including market, credit, liquidity, and foreign exchange risk. Nationwide Children's believes the carrying amount of these financial instruments in the consolidated balance sheets is a reasonable estimate of its ownership interest in the private equities. Because some of these financial instruments are not readily marketable, the estimated carrying value is subject to uncertainty and, therefore, may differ from the value that would have been used had a public market for such financial instruments existed. Nationwide Children's risk related to private equities is limited to its carrying value plus amounts committed to private equity as disclosed in Note 5. The private equity investments also have certain liquidity restrictions which generally range for the life of the fund. Once capital is contributed to a private equity fund, distribution timing is subject to the manager during the life of the fund.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

The carrying amounts of the variable rate, long-term debt, as detailed in Note 8, approximate their fair values. The fair value of the fixed-rate, long-term debt is estimated using a discounted cash flow analysis, based on current incremental borrowing rates for similar types of borrowing arrangements. The fair value of the fixed rate, long-term debt at December 31, 2019 and 2018, is approximately \$563,133,000 (carrying value \$505,360,000) and \$390,897,000 (carrying value \$365,470,000), respectively. Nationwide Children's debt obligations are classified consistent with Level 2 of the fair value hierarchy.

The following tables set forth Nationwide Children's assets and liabilities measured at fair value on a recurring basis as of December 31, aggregated by the level in the fair valued hierarchy within which those measurements are measured:

	2019			Total Fair Value
	Level 1	Level 2	Level 3	
	<i>(In Thousands)</i>			
Assets				
Cash and cash equivalents	\$ 245,371	\$ —	\$ —	\$ 245,371
Fixed income:				
U.S. Treasury bonds	—	30,801	—	30,801
U.S. Treasury notes	—	97,311	—	97,311
U.S. Government agencies	—	42,017	—	42,017
Corporate obligations	—	267,479	—	267,479
Foreign obligations	—	30,699	—	30,699
Mutual funds	321,438	3,436	—	324,874
Equities – mutual funds:				
Domestic large-cap indexed	946,179	—	—	946,179
Domestic mid-cap indexed	152,302	—	—	152,302
Domestic small-cap	122,511	—	—	122,511
International	535,388	—	—	535,388
Equities – domestic small-cap	124,774	—	—	124,774
Technology commercialization	400	—	—	400
Other	—	806	—	806
Total assets	<u>\$ 2,448,363</u>	<u>\$ 472,549</u>	<u>\$ —</u>	<u>\$ 2,920,912</u>
Liabilities				
Interest rate swaps	\$ —	\$ 34,865	\$ —	\$ 34,865
Total liabilities	<u>\$ —</u>	<u>\$ 34,865</u>	<u>\$ —</u>	<u>\$ 34,865</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

6. Fair Value Measurements (continued)

	2018			Total Fair Value
	Level 1	Level 2	Level 3	
	<i>(In Thousands)</i>			
Assets				
Cash and cash equivalents	\$ 121,883	\$ –	\$ –	\$ 121,883
Fixed income:				
U.S. Treasury bonds	–	23,055	–	23,055
U.S. Treasury notes	–	74,993	–	74,993
U.S. Government agencies	–	77,974	–	77,974
Corporate obligations	–	191,488	–	191,488
Foreign obligations	–	30,167	–	30,167
Mutual funds	239,082	4,949	–	244,031
Equities – mutual funds:				
Domestic large-cap indexed	763,090	–	–	763,090
Domestic mid-cap indexed	117,120	–	–	117,120
Domestic small-cap	94,179	–	–	94,179
International	413,237	–	–	413,237
Equities – domestic small-cap	95,500	–	–	95,500
Technology commercialization	1,389	–	–	1,389
Other	–	441	–	441
Total assets	\$ 1,845,480	\$ 403,067	\$ –	\$ 2,248,547
Liabilities				
Interest rate swaps	\$ –	\$ 22,951	\$ –	\$ 22,951
Total liabilities	\$ –	\$ 22,951	\$ –	\$ 22,951

The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are reasonable estimates of fair value due to the short-term nature of these financial instruments.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

7. Professional Liability Self-Insurance and Litigation

Nationwide Children's is subject to threatened legal actions, which arise in the normal course of its operating activities. Nationwide Children's risk management program regularly monitors its operations for potential claims. Various claimants have asserted professional and patient general liability claims for incidents that may give rise to litigation against Nationwide Children's. The claims are in various stages of evaluation and some ultimately may be brought to trial. There are also known incidents that have occurred through December 31, 2019, which may result in the assertion of additional claims, and there may be other claims related to unreported incidents arising from services provided to patients as of December 31, 2019.

Nationwide Children's has employed independent actuaries to estimate the ultimate cost, if any, of the settlement of such claims. Accrued professional liability losses have been discounted at an annual rate of 1.45% at December 31, 2019 and 2018, and, in management's opinion, provide adequate reserves for loss contingencies. As the actuarially determined accrual for professional and general liability is an estimate, the possibility exists that the estimate could be revised by a material amount in the near term.

To fund its self-insurance liability, Nationwide Children's maintains a trustee-held investment fund. Under the trust agreement, the trust assets can only be used for payment of professional and patient general liability losses, related expenses, and the cost of administering the trust.

On June 6, 2014, the United States Department of Treasury (DOT) concluded that the Hospital had violated certain provisions of the Code of Federal Regulations, which governs the use of the State and Local Government Series (SLGS) securities over a period from 2008 through 2012 in connection with advanced refunding of tax-exempt debt. As a consequence, the DOT suspended the Hospital from participating in the SLGS program for five years, with the possibility of a waiver with respect to certain purchases of SLGS securities. The Hospital disagreed with the DOT's decision, but elected not to contest the conclusion or suspension in court. On May 13, 2016, the United States Department of Justice (DOJ) informed the Hospital of its intention to investigate the Hospital's use of SLGS securities under the False Claims Act. The investigation remains in its early stages, and the Hospital has had only preliminary discussions with the DOJ. At this time, the Hospital cannot predict the outcome of the DOJ investigation, including the materiality of any potential monetary consequences, and the Hospital cannot presently estimate the amount of contingent liability, if any, and therefore no amount has been recognized in the consolidated financial statements. The DOJ's investigation and related future claims, if any, if decided adversely to the interests of the Hospital, could be material to the Hospital.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt

Long-term debt consisted of the following at December 31:

	<u>2019</u>	<u>2018</u>
	<i>(In Thousands)</i>	
Hospital Improvement Revenue and Improvement Bonds, Series 2019A	\$ 51,850	\$ —
Hospital Improvement Revenue and Improvement Bonds, Series 2019B	92,150	—
Hospital Revenue Refunding and Improvement Bonds, Series 2017A	93,290	93,290
Hospital Revenue Refunding and Improvement Bonds, Variable Rate Demand, Series 2017B	45,615	45,875
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2016A	8,100	9,295
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2016B	28,155	29,975
Hospital Revenue Refunding Bonds, Series 2016C	128,960	129,290
Hospital Improvement Revenue Bonds, Series 2015A	75,000	75,000
Hospital Improvement Revenue Bonds, Variable Rate Demand, Series 2015B	25,000	25,000
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2014A	10,735	12,405
Hospital Revenue Refunding Bonds, Adjustable Rate, Series 2014B	45,580	45,580
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2013A	34,345	35,990
Hospital Revenue Refunding Bonds, Variable Rate Demand, Series 2013B	15,675	16,965
Hospital Improvement Revenue Bonds, Series 2012A	64,110	65,705
Hospital Improvement Revenue Bonds, Series 2009	—	2,185
Hospital Improvement Revenue Bonds, Variable Rate Demand, Series 2008B	43,280	43,585
Finance lease obligations	1,905	—
Total long-term debt, including current portion	<u>763,750</u>	630,140
Bond discounts, premium and issuance cost – net	37,030	17,555
Less current portion of bonds and finance lease obligations	<u>(111,284)</u>	<u>(80,575)</u>
	<u>\$ 689,496</u>	<u>\$ 567,120</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In November 2019, the County of Franklin, Ohio (the County) issued \$51,850,000 of Hospital Improvement Revenue Bonds (the 2019A Bonds). The 2019A Bonds consisted of \$51,850,000 term bonds due in 2048. The term bonds bear annual interest at 5%. The 2019A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In November 2019, the County of Franklin, Ohio (the County) issued \$92,150,000 of Hospital Improvement Revenue Bonds (the 2019B Bonds). The 2019B Bonds consisted of \$92,150,000 term bonds due in 2050. The term bonds are taxable and bear annual interest at 3.38%. The 2019B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and a portion of the proceeds were used to fund the interest rate swap termination payment described below. In March 2019, Nationwide Children's entered into a taxable interest rate swap agreement with the intent of hedging the interest rate risk related to the 2019B Bonds. The notional amount of this agreement was \$75,000,000. The agreement was terminated in November 2019, and the fair value of the swap resulted in a termination payment of approximately \$15,408,000 and is included in other non-operating gains (losses) – net for the year ended December 31, 2019.

In November 2017, the County of Franklin, Ohio (the County) issued \$93,290,000 of Hospital Revenue Refunding and Improvement Bonds (the 2017A Bonds). The 2017A Bonds consisted of \$68,825,000 serial bonds as of December 31, 2019 and 2018, maturing in varying amounts from 2028 through 2039; \$12,935,000 of term bonds due in 2044; and \$11,530,000 of term bonds due in 2047. The serial bonds bear annual interest at rates ranging from 3.125% to 5% as of December 31, 2019 and 2018. The term bonds due in 2044 and 2047 bear annual interest at 4%. The 2017A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and for the current refunding of a portion of the 2008D bonds.

In November 2017, the County issued \$46,150,000 of Hospital Revenue Refunding and Improvement Bonds (the 2017B Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments beginning on November 1, 2018, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. The bonds bear annual interest at an adjustable rate, which was 1.63% and 2.61% at December 31, 2019 and 2018, respectively. The 2017B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities, and for the current refunding of a portion of the 2008D bonds.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In April 2016, the County issued \$47,670,000 of Hospital Revenue Refunding Bonds (the 2016A and 2016B Bonds). These bonds have been purchased by a bank to which Nationwide Children's will make varying principal payments beginning on May 1, 2017, and ending on May 1, 2026. On May 1, 2026 (expiration date of the bank purchase agreement), \$16,125,000 of unpaid principal will remain outstanding. The bonds bear annual interest at an adjustable rate, which was 1.64% and 2.07% annually as of December 31, 2019 and 2018, respectively, payable monthly. The 2016A and 2016B Bonds were issued for the purpose of current refunding of the 2008C and 2008F Bonds.

In November 2016, the County issued \$129,290,000 of Hospital Revenue Refunding Bonds (the 2016C Bonds). The 2016C Bonds consisted of \$61,395,000 and \$61,725,000 serial bonds as of December 31, 2019 and 2018, respectively, maturing in increasing amounts from 2019 through 2036; \$9,140,000 term bonds due in 2031, and \$58,425,000 term bonds due in 2040. The serial bonds bear interest at annual rates ranging from 3.25% to 5% as of December 31, 2019 and 2018. The term bonds due in 2031 and 2040 bear annual interest at 5% and 4%, respectively. The 2016C Bonds were issued for the purpose of advance refunding portions of the 2008A and 2009 Bonds.

In May 2015, the County issued \$75,000,000 of Hospital Improvement Revenue Bonds (the 2015A Bonds). The bonds consisted of \$75,000,000 of term bonds due in 2045. The term bonds bear annual interest at 4%. The 2015A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

In May 2015, the County issued \$25,000,000 of Hospital Improvement Revenue Bonds (the 2015B Bonds). The bonds mature in 2045, but are subject to redemption prior to maturity under various scenarios. The 2015B bonds bear annual interest at a variable rate, which was 1.63% and 1.77% as of December 31, 2019 and 2018, respectively, payable monthly. Since the 2015B Bonds are remarketed weekly, they are classified within current portion of long-term debt in the consolidated balance sheets. They were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In May 2015, the County issued \$17,225,000 of Hospital Revenue Refunding Bonds (the 2014A Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning on May 1, 2016, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. The bonds bear annual interest at an adjustable rate, which was 1.63% and 2.52% as of December 31, 2019 and 2018, respectively, payable monthly.

In May 2015, the County issued \$45,580,000 of Hospital Revenue Refunding Bonds (the 2014B Bonds). These bonds were purchased by a bank and no principal payments are due during the term of the agreement. On May 1, 2025 (expiration date of the bank purchase agreement), \$45,580,000 of unpaid principal will remain outstanding. The bonds bear annual interest at an adjustable rate, which was 1.67% and 2.10% as of December 31, 2019 and 2018, respectively, payable monthly.

In June 2013, the County issued \$44,155,000 of Hospital Revenue Refunding Bonds (the 2013A Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning November 1, 2013, and ending November 1, 2019, at which time the bank purchase agreement was terminated. The 2013A Bonds bear interest at an annual adjustable rate, which was 1.63% and 2.38% as of December 31, 2019 and 2018, respectively, payable monthly.

In June 2013, the County issued \$22,830,000 of Hospital Revenue Refunding Bonds (the 2013B Bonds). These bonds were purchased by a bank to which Nationwide Children's made varying principal payments, beginning on May 1, 2014, and ending on November 1, 2019, at which time the bank purchase agreement was terminated. The 2013B Bonds bear annual interest at an adjustable rate, which was 1.63% and 2.38% as of December 31, 2019 and 2018, respectively, payable monthly.

In May 2012, the County issued \$75,000,000 of Hospital Improvement Revenue Bonds (the 2012A Bonds). The 2012A Bonds consisted of \$14,110,000 and \$15,705,000 serial bonds as of December 31, 2019 and 2018, respectively, maturing in varying amounts through 2027, and \$50,000,000 term bonds due in 2042. The serial bonds bear annual interest at rates ranging from 3% to 5% as of December 31, 2019 and 2018. The term bonds bear annual interest at 5%. The 2012A Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In December 2009, the County issued \$100,000,000 of Hospital Improvement Revenue Bonds (the 2009 Bonds). The 2009 Bonds consisted of \$2,185,000 of serial bonds as of December 31, 2018. The 2009 Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital and Research Institute facilities. A substantial portion of the 2009 Bonds were paid through an advance refunding (2016C Bonds).

In May 2008, the County issued \$45,000,000 of Hospital Improvement Revenue Bonds (the 2008B Bonds). The bonds are subject to a mandatory sinking fund into which Nationwide Children's makes varying principal payments, beginning on November 1, 2013, and ending on November 1, 2040. The 2008B Bonds bear annual interest at a variable rate, which was 1.63% and 1.77% as of December 31, 2019 and 2018, respectively, payable monthly. Since the 2008B Bonds are remarketed weekly, they are classified within the current portion of long-term debt in the consolidated balance sheets. The 2008B Bonds were issued for the purpose of financing a portion of the cost of acquiring, constructing, equipping, installing and improving certain Hospital facilities.

The owners of the 2017B, 2014A, 2013A, and 2013B Bonds have the option to demand payment of their outstanding bonds. On November 1, 2019, Nationwide Children's entered into Stand-by Bond Purchase Agreements (the Agreements) for each of these bond issues with a bank which require the remarketing agent to utilize its best efforts to remarket any such bonds that may be tendered for payment. In the event any such bonds cannot be remarketed, the Agreements provide that the bank will provide payment for the bonds tendered. Should certain events occur, the amounts due to the bank will be converted to a term loan, for which Nationwide Children's has an obligation to make payment over three years, in quarterly payments, plus any accrued interest.

The owners of the 2015B and 2008B Bonds have the option to demand payment of their outstanding bonds. Should the remarketing agent be unsuccessful in remarketing these bonds, Nationwide Children's is providing its own liquidity as the repayment source to the bondholders.

Interest on the 2019A Bonds, 2019B Bonds, 2017A Bonds, 2016C Bonds, 2015A Bonds, and 2012A Bonds is payable semi-annually on May 1 and November 1 of each year.

Nationwide Children's made interest payments on long-term debt of \$17,245,000 and \$16,940,000 during 2019 and 2018, respectively.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

8. Long-Term Debt (continued)

In connection with the issuance of the Bonds, the County acquired title to substantially all of the Hospital's facilities and real property. The facilities and real property are, in turn, being leased to the Hospital through 2052, the latest mandatory retirement date of the Bonds, with payment terms equal to the debt service requirements of the Bonds. A provision of the lease grants an option to the Hospital to purchase the facilities for a nominal sum after provision has been made to retire the Bonds. The Hospital's facilities and real property are accounted for as a finance lease in the consolidated balance sheets.

Provisions of the Bonds require Nationwide Children's to, among other things, comply with certain financial ratios, restrict additional encumbrances, restrict the sale or acquisition of certain assets, or merge with another entity. As of December 31, 2019 and 2018, Nationwide Children's was in compliance with its debt covenants.

Aggregate scheduled maturities of long-term debt in each of the following five years are: 2020 – \$12,730,000; 2021 – \$13,195,000; 2022 – \$13,675,000; 2023 – \$14,180,000 and 2024 – \$14,710,000.

9. Leases

Nationwide Children's has operating and finance leases for real estate, personal property and equipment. Effective January 1, 2019, Nationwide Children's determines if an arrangement is a lease at the inception of a contract. Operating lease right-of-use assets are included in other noncurrent assets and operating lease liabilities are included in other current and long-term liabilities in the consolidated balance sheets. Nationwide Children's had right-of-use assets and lease liabilities for operating leases totaling approximately \$25,246,000 and \$26,814,000, respectively, at December 31, 2019. Finance lease right-of-use assets are included in property and equipment and the related lease liabilities are included in current portion of long-term debt and long-term debt in the consolidated balance sheets. Nationwide Children's had right-of-use assets and lease liabilities for finance leases totaling approximately \$1,686,000 and \$1,905,000, respectively, at December 31, 2019. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheets.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

9. Leases (continued)

Nationwide Children’s has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, Nationwide Children’s elected the permitted practical expedient to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use assets represent Nationwide Children’s right to use an underlying asset during the lease term and lease liabilities represent Nationwide Children’s obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date based on the net present value of fixed lease payments over the lease term. Nationwide Children’s lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of the operating leases do not provide an implicit rate, Nationwide Children’s uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Nationwide Children’s considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term.

Operating expenses for the leasing activity of Nationwide Children’s as lessee for the year ended December 31, 2019, are as follows (in thousands):

	<u>Classification</u>	<u>Amount</u>
Operating lease expense	Facilities expense	\$ 6,251
Financing lease interest	Interest expense	5
Financing lease amortization	Depreciation and amortization	67
Total lease cost		<u>\$ 6,323</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

9. Leases (continued)

Supplemental cash flow information for the year ended December 31, 2019, is as follows (in thousands):

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases	\$ 6,325
Operating cash flows from finance leases	5
Financing cash flows from finance leases	58
Total	<u>\$ 6,388</u>

The aggregate future lease payments for operating and finance leases as of December 31, 2019, were as follows:

	<u>Operating</u>	<u>Finance</u>
	<i>(In Thousands)</i>	
2020	\$ 6,266	\$ 190
2021	5,371	193
2022	4,446	196
2023	3,363	199
2024	2,886	202
Thereafter	9,484	1,028
Total lease payments	<u>31,816</u>	<u>2,008</u>
Less: imputed interest	(5,002)	(103)
Present value of lease liabilities	<u>\$ 26,814</u>	<u>\$ 1,905</u>

Average lease terms and discount rates were as follows as of December 31, 2019:

Weighted-average remaining lease term (years):

Operating leases	6.9
Finance leases	9.7

Weighted-average discount rate:

Operating leases	5.0%
Finance leases	5.0%

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Derivatives

Nationwide Children's has entered into various interest rate swap agreements with the intent of mitigating Nationwide Children's cash flow risk relating to changes in the variable interest rates of its bonds as listed within the following table. Under the swap agreements, Nationwide Children's pays interest at fixed rates (see table below) and receives interest at variable rates. Net interest paid or received under the swap agreements is included in interest expense. The following schedule outlines the terms and fair values of the interest rate swap agreements.

	Series 2008B	Series 2017B	Series 2013A	Series 2013B	Series 2014A	Series 2014B	Series 2016A	Series 2016B
Notional amount at December 31, 2019	\$ 43,280	\$ 45,390	\$ 6,880	\$ 15,575	\$ 10,735	\$ 45,580	\$ 8,065	\$ 28,020
Effective date	5-1-08	11-1-10	11-1-06	9-23-05	5-1-15	5-1-15	12-12-02	9-1-05
Termination date	11-1-40	11-1-33	11-1-25	5-1-29	5-1-25	5-1-35	11-1-25	5-1-31
Fixed annual rate	4.13%	3.22%	3.66%	3.19%	1.78%	2.06%	3.28%	3.57%
Fair value at December 31, 2017	(13,694)	(8,225)	(831)	(1,642)	(224)	(2,688)	(832)	(4,156)
Unrealized gain	2,355	1,578	248	452	145	1,202	257	965
Credit risk adjustment	(243)	(79)	2	(2)	—	(34)	2	(16)
Fair value at December 31, 2018	(11,582)	(6,726)	(581)	(1,192)	(79)	(1,520)	(573)	(3,207)
Unrealized loss	(4,927)	(2,422)	(10)	(305)	(161)	(2,968)	(33)	(714)
Credit risk adjustment	103	(11)	(2)	(2)	1	26	(2)	(7)
Fair value at December 31, 2019	\$ (16,406)	\$ (9,159)	\$ (593)	\$ (1,499)	\$ (239)	\$ (4,462)	\$ (608)	\$ (3,928)

In January 2009, Nationwide Children's entered into a speculative interest rate swap. The initial notional amount of this interest rate swap agreement was \$45,000,000, and the effective date of the transaction was January 1, 2011. Nationwide Children's pays interest based on 100% of the monthly Securities Industry and Financial Markets Association (SIFMA) Municipal Swap Index, and receives interest based on 100.89% of the 3-month LIBOR. The notional amount was \$43,280,000 and \$43,585,000 at December 31, 2019 and 2018, respectively. The fair value was \$2,515,000 and \$3,280,000 at December 31, 2019 and 2018, respectively, and the asset is netted against the interest rate swap liability in the consolidated balance sheets.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Derivatives (continued)

In December 2018, Nationwide Children’s entered into a speculative interest rate swap agreement. The initial, and current, notional amount of this interest rate swap agreement was \$100,000,000, and the effective date of the transaction was January 1, 2020. Nationwide Children’s will pay interest based on 67% of 1-month LIBOR, and receives interest based on 55.33% of 10-year LIBOR. The fair value was \$370,000 at December 31, 2019, and the asset is netted against the interest rate swap liability in the consolidated balance sheet. The fair value was \$(771,000) at December 31, 2018, and the liability is included in the interest rate swap liability in the consolidated balance sheet.

In July 2019, Nationwide Children’s entered into an interest rate swap agreement with the intent of hedging Nationwide Children’s interest rate risk related to a prospective bond refunding planned for May 2022. The notional amount of this interest rate swap agreement was \$61,305,000, and the effective date is May 1, 2022. Nationwide Children’s will pay interest at a fixed rate of 1.78% and will receive interest based on the SIFMA Municipal Swap Index. The fair value was \$(856,000) at December 31, 2019, and the liability is included in the interest rate swap liability in the consolidated balance sheet.

Nationwide Children’s has recorded the fair value of the interest rate swap agreements of \$(34,865,000) and \$(22,951,000) as a long-term liability in the consolidated balance sheets as of December 31, 2019 and 2018, respectively. The change in fair market value of the interest rate swap agreements of \$(11,914,000) and \$6,337,000 in 2019 and 2018, respectively, is included in other non-operating gains.

The following table presents the fair value of derivative instruments, location of the related instruments in the consolidated balance sheets and the related notional amounts of the derivative instruments as of December 31, 2019 and 2018:

	Derivative Liabilities		
	Balance Sheet Location	Fair Value	Notional Amount
	<i>(In Thousands)</i>		
Derivatives not designated as hedging instruments:			
Interest rate contracts – 2019	Interest rate swaps	\$ 34,865	\$ 408,110
Interest rate contracts – 2018	Interest rate swaps	\$ 22,951	\$ 354,600

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

10. Derivatives (continued)

Nationwide Children’s made net payments on interest rate swaps of approximately \$3,276,000 and \$3,832,000 during 2019 and 2018, respectively, which are recorded within interest expense, net of the change in accruals for these payments.

11. Defined Benefit Plan

Nationwide Children’s has a defined benefit pension plan (the Plan) for employees who meet certain requirements as to age and length of service. Nationwide Children’s funding policy is to make at least the minimum annual contributions required by applicable regulations.

The Plan was curtailed effective December 31, 1996, with respect to: (a) any employee under the age of 45, (b) any employee over the age of 45 who was not fully vested in his or her accrued benefit under the Plan, and (c) any other participant who elected to cease his or her participation in the Plan (affected participants). At that time, the accrued benefits of each affected participant became fully vested and non-forfeitable.

The following tables set forth the change in benefit obligation, change in plan assets, funded status, and components of net periodic benefit cost of the Plan:

	December 31	
	2019	2018
	<i>(In Thousands)</i>	
Change in benefit obligation		
Benefit obligation, beginning of the year	\$ 82,848	\$ 89,893
Service cost	790	630
Interest cost	3,187	2,890
Actuarial losses (gains)	7,874	(4,358)
Benefits paid	<u>(6,645)</u>	<u>(6,207)</u>
Benefit obligation, end of year	88,054	82,848
Change in plan assets		
Fair value of plan assets, beginning of the year	64,463	72,951
Actual return on plan assets	13,029	(2,984)
Employer contributions	1,699	703
Benefits paid	<u>(6,645)</u>	<u>(6,207)</u>
Fair value of plan assets, end of the year	<u>72,546</u>	<u>64,463</u>
Funded (deficit)	<u>\$ (15,508)</u>	<u>\$ (18,385)</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

	Year Ended December 31	
	2019	2018
	<i>(In Thousands)</i>	
Components of net periodic pension cost		
Service cost	\$ 790	\$ 630
Interest cost	3,187	2,890
Expected return on plan assets	(4,635)	(4,754)
Amortization of net loss	1,195	1,350
Net periodic pension cost	<u>\$ 537</u>	<u>\$ 116</u>

Weighted average assumptions used to determine benefit obligations as of December 31 are as follows:

	2019	2018
Discount rate	2.84%	3.95%
	Pri-2012 with fully generational projection using scale MP-2019	RP-2014 with fully generational projection using scale MP-2018
Mortality		

Weighted average assumptions used to determine net periodic pension cost for the years ended December 31:

	2019	2018
Discount rate	3.95%	3.29%
Expected return on plan assets	7.00%	7.00%
	2019 PPA optional combined mortality	2018 PPA optional combined mortality
Mortality		

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

Included as a reduction in net assets without donor restrictions are actuarial losses of \$32,665,000 and \$34,397,000 at December 31, 2019 and 2018, respectively, which will be recognized in net periodic pension cost in future periods.

The accumulated benefit obligation of the Plan at December 31, 2019 and 2018, was \$88,053,000 and \$82,847,000, respectively.

Expected benefit payments for the next ten years are: 2020 – \$6,168,000; 2021 – \$6,187,000; 2022 – \$6,197,000; 2023 – \$6,129,000; 2024 – \$6,030,000 and 2025 through 2029 – \$28,357,000.

The allocation of Plan assets by major category as a percentage of total Plan assets is set forth in the following table:

	December 31			
	2019		2018	
	Actual	Target	Actual	Target
Domestic equities	53%	43%	53%	43%
International equities	10	7	8	7
Fixed income and cash equivalents	37	50	39	50
	100%	100%	100%	100%

The target asset allocations are designed to match expected returns with the time horizon for the liabilities of the Plan, and are periodically reviewed and approved by the Finance Committee of the Board of Directors. The use of derivatives is currently not permitted by the Plan’s investment policy. The expected long-term rate of return assumption is based upon historical returns and management’s belief that future returns will approximate historical returns over a long-term time horizon.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

The fair value of plan assets at December 31 is as follows:

	2019			
	Level 1	Level 2	Level 3	Total Fair Value
	<i>(In Thousands)</i>			
Cash and cash equivalents	\$ 3,718	\$ –	\$ –	\$ 3,718
Fixed income:				
U.S. Treasury bonds and notes	–	9,289	–	9,289
U.S. Government agencies	–	2,358	–	2,358
Corporate obligations	–	11,252	–	11,252
Equities – mutual funds:				
Domestic large-cap indexed	27,764	–	–	27,764
Domestic mid-cap indexed	4,443	–	–	4,443
Domestic small-cap indexed	6,660	–	–	6,660
International	7,062	–	–	7,062
Total	\$ 49,647	\$ 22,899	\$ –	\$ 72,546
	2018			
	Level 1	Level 2	Level 3	Total Fair Value
	<i>(In Thousands)</i>			
Cash and cash equivalents	\$ 1,972	\$ –	\$ –	\$ 1,972
Fixed income:				
U.S. Treasury bonds and notes	–	9,375	–	9,375
U.S. Government agencies	–	3,729	–	3,729
Corporate obligations	–	10,217	–	10,217
Equities – mutual funds:				
Domestic large-cap indexed	24,312	–	–	24,312
Domestic mid-cap indexed	3,794	–	–	3,794
Domestic small-cap indexed	5,770	–	–	5,770
International	5,294	–	–	5,294
Total	\$ 41,142	\$ 23,321	\$ –	\$ 64,463

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

11. Defined Benefit Plan (continued)

Fair value methodologies for Level 1, 2 and 3 are consistent with the inputs described in Note 6.

The Hospital estimates that it will make a contribution of approximately \$2,471,000 to the Plan during 2020. The Hospital estimates that it will amortize \$1,549,000 of the net actuarial losses from net assets without donor restrictions into net periodic pension cost during 2020.

12. Defined Contribution Plans

Effective January 1, 1997, the Matching Plan was amended and renamed as the Nationwide Children's Hospital Employee Defined Contribution Plan (Defined Contribution Plan). The Defined Contribution Plan includes both an employee matching contribution and an additional employer defined contribution and contains provisions specifically permitting affected participants to transfer distributions received from the revised pension plan. The employer defined contribution is based upon certain percentages of employees' wages, which are determined based upon length of service and income levels.

Nationwide Children's provides a 403(b) matching contribution plan for essentially all employees who have met specified service requirements. Under the plan, Nationwide Children's matches 50% of the first 3% of salaries contributed by each participant, up to a maximum of 1.5% of the participant's salary.

Nationwide Children's incurred expenses related to these plans totaled \$38,672,000 and \$37,250,000 during 2019 and 2018, respectively. PAA incurred expenses related to these plans totaled \$8,194,000 and \$7,932,000 during 2019 and 2018, respectively.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

13. Property and Equipment

Details of property and equipment are summarized as follows as of December 31:

	<u>2019</u>	<u>2018</u>
	<i>(In Thousands)</i>	
Land and land improvements	\$ 91,459	\$ 86,075
Buildings and improvements	1,431,409	1,306,101
Equipment	371,811	372,344
Construction-in-progress	<u>200,460</u>	<u>170,273</u>
	2,095,139	1,934,793
Allowances for depreciation	<u>(661,696)</u>	<u>(602,499)</u>
	<u>\$ 1,433,443</u>	<u>\$ 1,332,294</u>

The ranges of useful lives associated with the following categories of property and equipment are as follows: land improvements – 8–15 years; buildings and improvements – 10–30 years; equipment – 5–20 years.

Capitalized computer software costs of \$5,300,000 and \$6,466,000 at December 31, 2019 and 2018, respectively, primarily related to clinical information systems, patient financial systems and enterprise resource planning software implementations are included in equipment. The related amortization included in depreciation expense in the consolidated statements of operations and changes in net assets was \$2,068,000 and \$2,834,000 for the years ended December 31, 2019 and 2018, respectively.

Outstanding commitments for the purchase of property and equipment were approximately \$15,035,000 and \$48,180,000 at December 31, 2019 and 2018, respectively. Nationwide Children’s expects to pay outstanding commitments at December 31, 2019, during 2020, using funds from operations and fundraising contributions.

14. Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at their net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of estimated future cash flows. The annual discounts applied to these amounts are computed by using an applicable annual interest rate to the year in which the promise is received, which is up to 4.5%.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

14. Pledges Receivable (continued)

The following is a summary of pledges receivable and the anticipated schedule of their receipt, for the year ended December 31:

	<u>2019</u>	<u>2018</u>
	<i>(In Thousands)</i>	
Gross unconditional pledges receivable	\$ 31,994	\$ 40,181
Less:		
Allowance for doubtful pledges	(1,001)	(1,185)
Unamortized discount	(2,970)	(4,033)
Net unconditional pledges receivable	<u>\$ 28,023</u>	<u>\$ 34,963</u>
Amounts due in:		
Less than one year	\$ 8,945	\$ 10,008
One to five years	22,193	29,432
Greater than five years	856	741
Total	<u>\$ 31,994</u>	<u>\$ 40,181</u>

15. Functional Expenses

Nationwide Children's provides a complete range of preventive, diagnostic, therapeutic and rehabilitative pediatric health services to residents within a 37 county area encompassing central, southern and southeastern Ohio. The table below presents expenses related to providing these services by both nature and function, for the years ended December 31:

	<u>2019</u>					
	<u>Healthcare</u>	<u>Management</u>				
	<u>Services</u>	<u>and General</u>	<u>Foundation</u>	<u>Research</u>	<u>Education</u>	<u>Total</u>
	<i>(In Thousands)</i>					
Salaries and benefits	\$ 727,347	\$ 272,330	\$ 4,380	\$ 87,247	\$ 32,930	\$1,124,234
Claims expense	585,530	-	-	-	-	585,530
Supplies	267,948	13,884	121	26,249	611	308,813
Purchased services	73,077	47,134	2,671	15,415	624	138,921
Interest	-	21,409	-	-	-	21,409
Depreciation and amortization	61,011	25,181	-	8,588	133	94,913
Other	93,159	100,711	1,080	8,690	2,063	205,703
Total operating expenses	<u>\$1,808,072</u>	<u>\$ 480,649</u>	<u>\$ 8,252</u>	<u>\$ 146,189</u>	<u>\$ 36,361</u>	<u>\$2,479,523</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

15. Functional Expenses (continued)

	2018					
	Healthcare Services	Management and General	Foundation	Research	Education	Total
	<i>(In Thousands)</i>					
Salaries and benefits	\$ 681,769	\$ 257,943	\$ 4,211	\$ 76,681	\$ 30,872	\$1,051,476
Claims expense	521,955	-	-	-	-	521,955
Supplies	215,351	11,560	87	25,676	640	253,314
Purchased services	68,171	40,373	2,572	13,208	478	124,802
Interest	-	21,344	-	-	-	21,344
Depreciation and amortization	60,971	24,041	-	9,459	108	94,579
Other	88,807	93,191	1,235	7,463	2,464	193,160
Total operating expenses	<u>\$1,637,024</u>	<u>\$ 448,452</u>	<u>\$ 8,105</u>	<u>\$ 132,487</u>	<u>\$ 34,562</u>	<u>\$2,260,630</u>

The consolidated financial statements report certain categories of expenses that are attributable to more than one supporting function. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries and benefits, which are allocated on a per full-time equivalent basis, and depreciation, which is allocated based on square footage.

16. Financial Assets and Liquidity Availability

As of December 31, 2019 and 2018, Nationwide Children's had a working capital surplus of \$333,377,000 and \$321,639,000, respectively.

Financial assets available for general expenditure within one year of the consolidated balance sheet date consist of the following:

	December 31	
	2019	2018
	<i>(In Thousands)</i>	
Financial assets:		
Cash and cash equivalents	\$ 304,557	\$ 318,793
Patient accounts receivable	307,800	273,491
Other assets	86,081	147,224
Assets limited as to use:		
Board-designated capital improvement	63,506	54,358
Board-designated other	2,629,204	1,972,169
Financial assets available for general expenditures within one year	<u>\$ 3,391,148</u>	<u>\$ 2,447,242</u>

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

16. Financial Assets and Liquidity Availability (continued)

Nationwide Children’s has certain board-designated assets limited as to use which are available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the qualitative information above. Nationwide Children’s has other assets limited as to use for donor-restricted purposes, debt service and for the professional liability captive insurance program. These assets limited as to use are not available for general expenditure within the next year and are not reflected in the amounts above. As part of Nationwide Children’s liquidity management plan, cash in excess of daily requirements is invested in short-term investments and money market funds.

17. Concentration of Credit Risk

In most cases, Nationwide Children’s grants credit without collateral to its patients, most of who are local residents and are insured under third-party payor agreements. The mix of the Hospital’s gross receivables from patients and third-party payors was as follows:

	December 31	
	2019	2018
Medicaid	37%	42%
Commercial	46	42
Other third-party payors	6	7
Patients’ responsibility	11	9
	100%	100%

18. Net Assets with Donor Restrictions

Net assets with donor restrictions are those whose use by Nationwide Children’s has been limited by donors to a specific time period or purpose or those that have been restricted by donors to be maintained by Nationwide Children’s in perpetuity. Investment return is allocated to net assets

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

18. Net Assets with Donor Restrictions (continued)

without donor restrictions and net assets with donor restrictions based on the respective net asset balances and the wishes of the donor. The nature and amounts of the net assets with donor restrictions are as follows:

	December 31	
	2019	2018
	<i>(In Thousands)</i>	
Net assets with donor restrictions:		
Program support	\$ 275,020	\$ 253,491
Research	67,161	55,697
	\$ 342,181	\$ 309,188

Nationwide Children’s endowment consists of approximately 200 individual, donor-restricted, funds established for various purposes. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. Nationwide Children’s classifies as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulations are added to the fund. Nationwide Children’s considers the following factors in making a determination to appropriate or accumulate donor-restricted funds: (1) the duration and preservation of the fund, (2) the purposes of the organization and the donor-restricted endowment fund, (3) general economic conditions, (4) the possible effect of inflation and deflation, (5) the expected total return from income and the appreciation of investments, (6) other resources of the organization, and (7) investment policies of the organization.

To satisfy its long-term rate-of-return objectives, Nationwide Children’s relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). A diversified asset allocation is targeted that places a greater emphasis on equity-based investments to achieve long-term return objectives within prudent risk considerations. Nationwide Children’s expects its endowment funds, over time, to provide an average rate of return of approximately 7% annually. Actual returns in any given year may vary from this amount.

Nationwide Children’s Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

18. Net Assets with Donor Restrictions (continued)

Nationwide Children’s has a policy of appropriating for distribution each year 5% of the spendable balance of its endowment. In establishing this policy, Nationwide Children’s considered the long-term expected return on its endowment. Accordingly, over the long-term, it is expected this spending policy will allow its endowment to grow at an average of 2% annually. This is consistent with Nationwide Children’s objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specified term, as well as to provide additional real growth through new gifts and investment return.

Nationwide Children’s had the following donor-restricted endowment-related activities:

	Change in Endowment Net Assets with Donor Restrictions for the Year Ended December 31	
	2019	2018
	<i>(In Thousands)</i>	
Endowment net assets, beginning of year	\$ 179,317	\$ 180,561
Investment return:		
Investment income	5,059	5,240
Unrealized gains (losses)	20,870	(12,838)
Total investment return	<u>25,929</u>	<u>(7,598)</u>
Contributions	7,298	11,551
Appropriation of endowment assets for expenditure	<u>(4,967)</u>	<u>(5,197)</u>
Endowment net assets, end of year	<u>\$ 207,577</u>	<u>\$ 179,317</u>

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to Consolidated Financial Statements (continued)

19. Subsequent Events

Due to the global viral outbreak caused by Coronavirus Disease 2019 (COVID-19) in 2020, there have been resulting effects which could negatively impact Nationwide Children's consolidated financial condition, including significant financial markets volatility, various temporary business closures and event cancellations, and other effects which could result in supply disruptions and/or decisions to defer elective procedures and other medical treatments at the Hospital as the broader impact of COVID-19 develops. The ultimate impact of these matters to the Hospital and its financial condition is presently unknown. The accompanying consolidated financial statements as of and for the year ended December 31, 2019, do not reflect the effects of these subsequent events.

The Hospital has evaluated and disclosed any subsequent events through April 23, 2020, which is the date the consolidated financial statements were issued. No subsequent events were identified that required recognition in the consolidated financial statements.

Supplementary Information

THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2019 - 12/31/2019

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF AGRICULTURE									
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2016-67015-24765	THE ROCKEFELLER UNIVERSITY	2016-67015-24765		\$12,144	\$35,071	RESEARCH AND DEVELOPMENT	\$63,933,702
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	60060409	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60060409		\$12,962	\$35,071	RESEARCH AND DEVELOPMENT	\$63,933,702
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	60060409	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60060409		\$9,965	\$35,071	RESEARCH AND DEVELOPMENT	\$63,933,702
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	ORD 2468-2017	COLUMBUS HEALTH DEPARTMENT	ORD 2468-2017		\$62	\$645,664	RESEARCH AND DEVELOPMENT	\$63,933,702
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	ORD 2339-2018	COLUMBUS HEALTH DEPARTMENT	ORD 2339-2018		\$483,964	\$645,664	RESEARCH AND DEVELOPMENT	\$63,933,702
WIC SPECIAL SUPPLEMENTAL NUTRITION PROGRAM FOR WOMEN, INFANTS, AND CHILDREN	10.557	ORD 2273-2019	COLUMBUS HEALTH DEPARTMENT	ORD 2273-2019		\$161,638	\$645,664	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD AND ADULT CARE FOOD PROGRAM	10.558	SCHOOL DISTRICT IRN #015432	STATE OF OHIO DEPARTMENT OF EDUCATION	SCHOOL DISTRICT IRN #015432		\$30,225	\$30,225	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL DEPARTMENT OF AGRICULTURE							\$710,960		
DEPARTMENT OF DEFENSE									
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0104				\$70,861	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810324				\$39,734	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810546				\$350,020	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810518			\$297,866	\$1,249,839	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1810547			\$112,874	\$200,742	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH1910371				\$92,841	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0420				\$67,776	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0420				-\$1,886	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	NTRAP-18-04	NATIONAL TRAUMA INSTITUTE	NTRAP-18-04		\$23,600	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	60067680	THE OHIO STATE UNIVERSITY	60067680		\$17,828	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	60067680	THE OHIO STATE UNIVERSITY	60067680		\$6,047	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	417439/URFAO: GR510697	UNIVERSITY OF ROCHESTER	417439/URFAO: GR510697		\$76,335	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	417439/URFAO: GR510697	UNIVERSITY OF ROCHESTER	417439/URFAO: GR510697		\$76,143	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	000518323-007	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518323-007		\$8,325	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	64894	THE HENRY M. JACKSON FNDTN	64894		\$43,865	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	60065213	THE OHIO STATE UNIVERSITY	60065213		\$13,965	\$2,336,035	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL DEPARTMENT OF DEFENSE						\$410,740	\$2,336,035		
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575	2018-VOCA-109853839	CRIME VICTIMS ASSISTANCE	2018-VOCA-109853839		-\$1	\$897,109	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2019-VOCA-132134707	CRIME VICTIMS ASSISTANCE	2019-VOCA-132134707		\$263,259	\$897,109	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2020-VOCA-132923982	CRIME VICTIMS ASSISTANCE	2020-VOCA-132923982		\$84,893	\$897,109	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2019-VOCA-132134686				\$174,181	\$897,109	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2019-VOCA-132924034				\$36,738	\$897,109	N/A	\$0
CRIME VICTIM ASSISTANCE	16.575	2020-SVAA-132923994	CRIME VICTIMS ASSISTANCE	2020-SVAA-132923994		\$2,370	\$897,109	RESEARCH AND DEVELOPMENT	\$63,933,702
CRIME VICTIM ASSISTANCE	16.575					-\$78	\$897,109	RESEARCH AND DEVELOPMENT	\$63,933,702
CRIME VICTIM ASSISTANCE	16.575	2018-VOCA-109853858				\$3,367	\$897,109	RESEARCH AND DEVELOPMENT	\$63,933,702
CRIME VICTIM ASSISTANCE	16.575	2018-VOCA-109853848				-\$98,289	\$897,109	RESEARCH AND DEVELOPMENT	\$63,933,702
CRIME VICTIM ASSISTANCE	16.575	2019-VOCA-132134627				\$208,284	\$897,109	RESEARCH AND DEVELOPMENT	\$63,933,702
CRIME VICTIM ASSISTANCE	16.575	2019-VOCA-132134690	CRIME VICTIMS ASSISTANCE	2019-VOCA-132134690	\$222,385	\$222,385	\$897,109	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL DEPARTMENT OF JUSTICE						\$222,385	\$897,109		

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
NATIONAL SCIENCE FOUNDATION									
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	1761880				\$36,316	\$36,316	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOLOGICAL SCIENCES	47.074	5506-NCH-NSF-9072	THE PENNSYLVANIA STATE UNIVERSITY	5506-NCH-NSF-9072		\$41,007	\$166,353	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOLOGICAL SCIENCES	47.074	5506-NCH-NSF-9072	THE PENNSYLVANIA STATE UNIVERSITY	5506-NCH-NSF-9072		\$32,151	\$166,353	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOLOGICAL SCIENCES	47.074	420-41-27A	IOWA STATE UNIVERSITY	420-41-27A		\$93,195	\$166,353	RESEARCH AND DEVELOPMENT	\$63,933,702
EDUCATION AND HUMAN RESOURCES	47.076	RESS13267	CASE WESTERN RESERVE UNIVERSITY	RESS13267		\$100,606	\$100,606	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL NATIONAL SCIENCE FOUNDATION							<u>\$303,275</u>		
DEPARTMENT OF EDUCATION									
TRIO UPWARD BOUND	84.047	P047M170582				\$3,438	\$278,330	N/A	\$0
TRIO UPWARD BOUND	84.047	P047M170582 - 18A				\$227,028	\$278,330	N/A	\$0
TRIO UPWARD BOUND	84.047	P047M170582 - 19				\$47,864	\$278,330	N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	1829	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	1829		\$43,795	\$41,663	N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	2112	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	2112		\$9,821	\$41,663	RESEARCH AND DEVELOPMENT	\$63,933,702
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES	84.181	1829	OHIO DEPARTMENT OF DEVELOPMENTAL DISABILITIES	1829		-\$11,953	\$41,663	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL DEPARTMENT OF EDUCATION							<u>\$319,993</u>		
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
		IBEM-IS - PROJECT #Z-38839-							
NATIONAL ORGANIZATIONS OF STATE AND LOCAL OFFICIALS INNOVATIONS IN APPLIED PUBLIC HEALTH RESEARCH	93.011	117	MICHIGAN PUBLIC HEALTH INSTITUTE	IBEM-IS - PROJECT #Z-38839-117		\$2,042	\$2,042	RESEARCH AND DEVELOPMENT	\$63,933,702
PUBLIC HEALTH EMERGENCY PREPAREDNESS	93.061	R03SH000048				\$18,125	\$18,125	RESEARCH AND DEVELOPMENT	\$63,933,702
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES - PREVENTION AND SURVEILLANCE	93.069	34225	OHIO DEPARTMENT OF HEALTH	34225		\$43,755	\$43,755	RESEARCH AND DEVELOPMENT	\$63,933,702
HOSPITAL PREPAREDNESS PROGRAM (HPP) AND PUBLIC HEALTH EMERGENCY PREPAREDNESS (PHEP) ALIGNED COOPERATIVE AGREEMENTS	93.074	14687	OHIO DEPARTMENT OF HEALTH	14687	\$74,594	\$111,955	\$111,955	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	CDC 17-18-436	HEMOPHILIA FOUNDATION OF MICHIGAN	CDC 17-18-436		\$202	\$22,042	N/A	\$0
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	CDC 18-19-436	HEMOPHILIA FOUNDATION OF MICHIGAN	CDC 18-19-436		\$21,840	\$22,042	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	CSP902718-4 / DYS01-0000019640	OHIO DEPT OF YOUTH SERVICES	CSP902718-4 / DYS01-0000019640		\$148,452	\$558,453	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	CSP902718-9	OHIO DEPT OF YOUTH SERVICES	CSP902718-9		\$172,631	\$558,453	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$12,087	\$558,453	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES	OHIO DEPT OF YOUTH SERVICES		\$14,152	\$558,453	N/A	\$0
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	90AP2678NCH	OHIO HEALTH RESEARCH INSTITUTE	90AP2678NCH		\$160,344	\$558,453	RESEARCH AND DEVELOPMENT	\$63,933,702
AFFORDABLE CARE ACT (ACA) PERSONAL RESPONSIBILITY EDUCATION PROGRAM	93.092	90AP2678NCH	OHIO HEALTH RESEARCH INSTITUTE	90AP2678NCH		\$50,787	\$558,453	RESEARCH AND DEVELOPMENT	\$63,933,702
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	1U01FD006883-01 REVISED				\$14,060	\$1,097	RESEARCH AND DEVELOPMENT	\$63,933,702
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	2001280580	JOHN HOPKINS UNIVERSITY	2001280580		-\$12,980	\$1,097	RESEARCH AND DEVELOPMENT	\$63,933,702
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	VUMC76678	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC76678		\$17	\$1,097	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MCHB 436 18-19	HEMOPHILIA FOUNDATION OF MICHIGAN	MCHB 436 18-19		\$12,964	\$441,160	N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	R40MC28316				\$43,290	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	226859	MASSACHUSETTS GENERAL HOSPITAL	226859		\$53	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	226859	MASSACHUSETTS GENERAL HOSPITAL	226859		\$157,062	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60060455	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60060455		-\$2,244	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60065448	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60065448		\$65,725	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	60070495	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60070495		\$52,617	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	KUHLTHAU NCH 226858	MASSACHUSETTS GENERAL HOSPITAL	KUHLTHAU NCH 226858		-\$3,566	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	226858-MOD004	MASSACHUSETTS GENERAL HOSPITAL	226858-MOD004		\$60,637	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	226858-MOD004	MASSACHUSETTS GENERAL HOSPITAL	226858-MOD004		\$30,552	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MCHB 436 19-20	HEMOPHILIA FOUNDATION OF MICHIGAN	MCHB 436 19-20		\$2,689	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6UA3MC11054-09-00	MASSACHUSETTS GENERAL HOSPITAL	6UA3MC11054-09-00		-\$306	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	6UA3MC11054-10-00	MASSACHUSETTS GENERAL HOSPITAL	6UA3MC11054-10-00		\$21,687	\$441,160	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	533435	UNIVERSITY OF NORTH CAROLINA	533435		\$534	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	533435	UNIVERSITY OF NORTH CAROLINA	533435		\$990	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	60067596	THE OHIO STATE UNIVERSITY	60067596		\$39,709	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	60072330	THE OHIO STATE UNIVERSITY	60072330		\$10,839	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5112047	UNIVERSITY OF NORTH CAROLINA	5112047		\$35,526	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	60066456	THE OHIO STATE UNIVERSITY	60066456		\$4,514	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1044863-10	THE UNIVERSITY OF UTAH	1044863-10		\$121,806	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	1R01DE027493-01	THE UNIVERSITY OF UTAH	1R01DE027493-01		-\$18	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	60071030	THE OHIO STATE UNIVERSITY	60071030		\$32,161	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5113295	UNIVERSITY OF NORTH CAROLINA	5113295		\$21,578	\$267,639	RESEARCH AND DEVELOPMENT	\$63,933,702
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	U03MC28844				-\$1,827	\$662,599	RESEARCH AND DEVELOPMENT	\$63,933,702
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	5 U03MC288440400			\$341,993	\$548,751	\$662,599	RESEARCH AND DEVELOPMENT	\$63,933,702
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	2 U03MC288440500			\$52,361	\$115,675	\$662,599	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	R49CE002106				-\$4,311	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6R49CE002106-05-06				\$81,239	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6R49CE002106-05-06				\$115,444	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6R49CE002106-05-06				\$31,732	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6R49CE002106-05-06				\$18,644	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6R49CE002106-05-06				\$80,848	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	6R49CE002106-05-06			\$77,867	\$174,457	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R49CE003074-01-00				\$70,163	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R49CE003074-01-00				\$63,908	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R49CE003074-01-00				\$13,748	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	1 R49CE003074-01-00				\$9,083	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	10045261-03	THE UNIVERSITY OF UTAH	10045261-03		-\$7,043	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	10045261-03	THE UNIVERSITY OF UTAH	10045261-03		\$62,042	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	10045261-03	THE UNIVERSITY OF UTAH	10045261-03		\$15,369	\$725,323	RESEARCH AND DEVELOPMENT	\$63,933,702

<i>Federal Awarding Agency/Program Title</i>	<i>Federal CFDA Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
HUMAN GENOME RESEARCH	93.172	U41HG007635	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-19-46	\$182,310	\$849,643	\$1,006,964	RESEARCH AND DEVELOPMENT	\$63,933,702
HUMAN GENOME RESEARCH	93.172	WU-19-46	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-19-46		\$57,471	\$1,006,964	RESEARCH AND DEVELOPMENT	\$63,933,702
HUMAN GENOME RESEARCH	93.172	WU-19-116	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-19-116		\$99,850	\$1,006,964	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R01DC013313				\$62,504	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-08				\$216,643	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-08				\$166,765	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-09				\$118,032	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC011818-09				\$83,175	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC003915-19				\$240,003	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC003915-20				\$183,496	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC015688-03			\$106,515	\$246,445	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC015688-04			\$26,200	\$106,421	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R21DC016709-02				\$12,024	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R13DC017389-01			\$35,550	\$35,550	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60057049-NCH	THE OHIO STATE UNIVERSITY	60057049-NCH		\$4,113	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60057049-NCH	THE OHIO STATE UNIVERSITY	60057049-NCH		\$2,436	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60051342	THE OHIO STATE UNIVERSITY	60051342		\$23,907	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60051342	THE OHIO STATE UNIVERSITY	60051342		\$28,808	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60069912	THE OHIO STATE UNIVERSITY	60069912		\$14,728	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R21DC016709	THE MEDICAL COLLEGE OF WISCONSIN	R21DC016709		\$137	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	60070611	THE OHIO STATE UNIVERSITY	60070611		\$8,270	\$1,553,457	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	1R61AT009632-01				-\$994	\$274,630	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	5R61AT009632-02				\$275,624	\$274,630	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL RESEARCH SERVICE AWARDS HEALTH SERVICES RESEARCH TRAINING	93.225	3201350919	CHILDREN'S HOSPITAL OF PHILADELPHIA	3201350919		\$88,410	\$88,410	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	JHU ID# 90060349/OLSHFSKI	JOHN HOPKINS UNIVERSITY	JHU ID# 90060349/OLSHFSKI		\$2,553	\$89,525	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	60066834	THE OHIO STATE UNIVERSITY	60066834		\$46,973	\$89,525	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	136514	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	136514		-\$300	\$89,525	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	136514	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	136514		\$39,463	\$89,525	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	FY20.861.001	UNIVERSITY OF COLORADO DENVER	FY20.861.001		\$836	\$89,525	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	3210920619	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	3210920619		\$35,199	\$46,892	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	3210920619	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	3210920619		\$11,693	\$46,892	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	1R21MH116206-01A1			\$11,371	\$110,436	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	5R21MH116206-02				\$101,398	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	1R01MH117594-01			\$125,003	\$205,645	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH117594-02			\$112,608	\$199,248	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	20002463	MCMMASTER UNIVERSITY	20002463		\$299,949	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	20002463	MCMASTER UNIVERSITY	20002463		\$59,689	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	568947	UNIVERSITY OF PENNSYLVANIA	568947		\$4	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	568947	UNIVERSITY OF PENNSYLVANIA	568947	\$22,297	\$1,468,381	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	568947	UNIVERSITY OF PENNSYLVANIA	568947	\$34,247	\$1,468,381	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	6131	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	6131		\$2,072	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	651	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	651		\$57,331	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	911	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	911		\$308,514	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	3004544097	REGENTS UNIVERSITY OF MICHIGAN	3004544097		\$12,651	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	3003322494	REGENTS UNIVERSITY OF MICHIGAN	3003322494		\$17,410	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	3004544097	REGENTS UNIVERSITY OF MICHIGAN	3004544097		\$3,142	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	60067394	THE OHIO STATE UNIVERSITY	60067394		\$20,780	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
MENTAL HEALTH RESEARCH GRANTS	93.242	60067394	THE OHIO STATE UNIVERSITY	60067394		\$13,568	\$1,468,381	RESEARCH AND DEVELOPMENT	\$63,933,702
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	SM062894	OHIO SUICIDE PREVENTION FOUNDATION	SM062894		\$78,697	\$97,091	RESEARCH AND DEVELOPMENT	\$63,933,702
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE	93.243	SM062894	OHIO SUICIDE PREVENTION FOUNDATION	SM062894		\$18,394	\$97,091	RESEARCH AND DEVELOPMENT	\$63,933,702
ADVANCED NURSING EDUCATION WORKFORCE GRANT PROGRAM	93.247	60055773	THE OHIO STATE UNIVERSITY	60055773		-\$712	-\$712	RESEARCH AND DEVELOPMENT	\$63,933,702
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	5 H4BH515471-10-00				\$253,920	\$331,620	RESEARCH AND DEVELOPMENT	\$63,933,702
POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	2 H4BH515471-11-00				\$77,700	\$331,620	RESEARCH AND DEVELOPMENT	\$63,933,702
ALCOHOL RESEARCH PROGRAMS	93.273	RAA025974A				\$3,010	\$194,906	RESEARCH AND DEVELOPMENT	\$63,933,702
ALCOHOL RESEARCH PROGRAMS	93.273	5R21AA025974-02				\$191,896	\$194,906	RESEARCH AND DEVELOPMENT	\$63,933,702
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R01DA042948-02				\$134,077	\$708,309	RESEARCH AND DEVELOPMENT	\$63,933,702
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3R01DA042948-02S1				\$119,826	\$708,309	RESEARCH AND DEVELOPMENT	\$63,933,702
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R01DA042948-03				\$365,598	\$708,309	RESEARCH AND DEVELOPMENT	\$63,933,702
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	60067560	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067560		\$59,959	\$708,309	RESEARCH AND DEVELOPMENT	\$63,933,702
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	60071383	THE OHIO STATE UNIVERSITY	60071383		\$9,048	\$708,309	RESEARCH AND DEVELOPMENT	\$63,933,702
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	60073028	THE OHIO STATE UNIVERSITY	60073028		\$19,801	\$708,309	RESEARCH AND DEVELOPMENT	\$63,933,702
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1R21EB026518-01				\$59,313	\$194,006	RESEARCH AND DEVELOPMENT	\$63,933,702
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R21EB026518-02				\$82,505	\$194,006	RESEARCH AND DEVELOPMENT	\$63,933,702
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1090547-401786	CARNEGIE MELLON UNIVERSITY	1090547-401786		\$30,140	\$194,006	RESEARCH AND DEVELOPMENT	\$63,933,702
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	1090547-401786	CARNEGIE MELLON UNIVERSITY	1090547-401786		\$22,048	\$194,006	RESEARCH AND DEVELOPMENT	\$63,933,702
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R21MD011767-02/3R21MD011767				\$217,765	\$425,959	RESEARCH AND DEVELOPMENT	\$63,933,702
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	1R01MD013881-01				\$208,194	\$425,959	RESEARCH AND DEVELOPMENT	\$63,933,702
TRANS-NIH RESEARCH SUPPORT	93.310	F0019-07 (FMRLY F8708-07)	NEW YORK UNIVERSITY	F0019-07 (FMRLY F8708-07)		\$16,292	\$16,292	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60060042	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60060042		-\$1	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60067461	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60067461		\$343,580	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60067461	THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION	60067461		\$297,299	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60062080	THE OHIO STATE UNIVERSITY	60062080		-\$226	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60066025	THE OHIO STATE UNIVERSITY	60066025		\$14,618	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	60070081	THE OHIO STATE UNIVERSITY	60070081		\$23,057	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	UL1TR002733	THE OHIO STATE UNIVERSITY	UL1TR002733		\$425	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	203-7853	DUKE UNIVERSITY	203-7853		\$2,059	\$680,811	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	210228-0619-17	THE JACKSON LABORATORY	210228-0619-17		\$6,007	\$10,686	RESEARCH AND DEVELOPMENT	\$63,933,702
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	210228-0620-17	THE JACKSON LABORATORY	210228-0620-17		\$4,679	\$10,686	RESEARCH AND DEVELOPMENT	\$63,933,702
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U01CA232488-01			\$89,393	\$714,769	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA231641-01			\$19,646	\$804,285	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1				\$3,400	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1				\$1,815	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U54CA232561-01A1				\$16,573	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	WU-17-316-MOD-11	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-17-316-MOD-11		-\$1,454	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	WU-17-316-MOD-2	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-17-316-MOD-2		\$7,660	\$1,547,048	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	1R01NR017533-01A1			\$205,465	\$289,459	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	5R01NR017533-02				\$264,236	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	60055113	THE OHIO STATE UNIVERSITY	60055113		\$25,693	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	60059902	THE OHIO STATE UNIVERSITY	60059902		\$5,954	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	60067619	THE OHIO STATE UNIVERSITY	60067619		\$5,134	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	60067619	THE OHIO STATE UNIVERSITY	60067619		\$27,775	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	1300202	DANA FARBER CANCER INSTITUTE	1300202		\$3,533	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	1300203	DANA FARBER CANCER INSTITUTE	1300203		\$9,390	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	RESS12999	CASE WESTERN RESERVE UNIVERSITY CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	RESS12999		\$21,982	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	304482	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	304482		\$22,861	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	304482	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	304482		\$44,010	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	305174	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	305174		\$34,282	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	305174	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	305174		\$26,179	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
NURSING RESEARCH	93.361	100720-550114	WAKE FOREST UNIVERSITY HEALTH SCIENCES	100720-550114		\$4,615	\$785,103	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01CA172723				-\$109	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA172723-06 REVISED			\$47,678	\$219,103	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01CA172713				\$416	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01CA183776				-\$3,265	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R21CA227926-01A1				\$92,070	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R21CA227926-01A1				\$15,393	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	G0G-0225/RAMIREZ	UNIVERSITY OF ARIZONA VANDERBILT UNIVERSITY MEDICAL CENTER	G0G-0225/RAMIREZ		\$23,315	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UNIV58725(1971-015745)	UNIVERSITY OF ARIZONA VANDERBILT UNIVERSITY MEDICAL CENTER	UNIV58725(1971-015745)		\$44,053	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CAUSE AND PREVENTION RESEARCH	93.393	WU-19-84	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-19-84		\$1,646	\$392,622	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA183730-05 REVISED				\$327,344	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-04				\$238,172	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-04				\$312,595	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-04				\$97,075	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	3U24CA196173-04S1				\$279,340	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	3U24CA196173-04S1				\$4,111	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-05				\$720,124	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-05				\$723,164	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-05				\$357,193	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-04				\$99,709	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-04				\$16	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-04				\$15,519	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-05				\$2,288	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196173-05				\$67,506	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	U24CA196175				-\$9	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-04				\$384,027	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-04				\$151,865	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-04				\$95,765	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-04			\$121,378	\$122,056	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-04				\$100,484	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	3U24CA196175-04S1			\$37,034	\$48,495	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	3U24CA196175-04S1				\$2,658	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$669,805	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$449,836	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$299,439	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05			\$109,124	\$109,124	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$654,082	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$22,747	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$49,704	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	SU24CA196175-05				\$5,416	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1U11CA239754-01				\$567,804	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$271,375	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$81,154	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$84,422	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$449,700	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$189,098	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$30,610	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$3,079	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	NRG BSB-NCH YR 1	NRG ONCOLOGY	NRG BSB-NCH YR 1		\$15,842	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205601	DANA FARBER CANCER INSTITUTE	1205601		\$9,694	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1205602	DANA FARBER CANCER INSTITUTE	1205602		\$127,178	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	60066393	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60066393		\$91,894	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	60066393	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60066393		\$52,914	\$8,384,414	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	1R21CA223104-01A1				\$158,649	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	N02-CM-62212	CHILDREN'S HOSPITAL OF PHILADELPHIA	N02-CM-62212		\$202	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	SUB55_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	SUB55_01	\$7,350	\$46,970	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	AALL1131	CHILDREN'S HOSPITAL OF PHILADELPHIA	AALL1131		\$706	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	NCORP PCR WO FP00017458_SUB59_	CHILDREN'S HOSPITAL OF PHILADELPHIA	NCORP PCR WO FP00017458_SUB59_		\$9,037	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00015221 SUB394 01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00015221 SUB394 01		-\$8,642	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	BIQSFP PCR: FP00021164_SUB57_0	CHILDREN'S HOSPITAL OF PHILADELPHIA	BIQSFP PCR: FP00021164_SUB57_0		\$1,815	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15329_SUB01_05	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP15329_SUB01_05		\$39,849	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	UFDSP00010880	UNIVERSITY OF FLORIDA CHILDREN'S HOSPITAL OF PHILADELPHIA	UFDSP00010880		-\$4,976	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP1522_SUB07_05	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP1522_SUB07_05		\$5,817	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00013087_SUB55	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00013087_SUB55		\$68,814	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00015221_SUB780_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00015221_SUB780_01		\$18,332	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15222 SUB10 04	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP15222 SUB10 04		\$15,371	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00013087_SUB66 01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00013087_SUB66 01		\$3,661	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15221 SUB549 01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP15221 SUB549 01		\$1,076	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP21482_SUB02_03	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP21482_SUB02_03		\$3,230	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	160877/159050	THE UNIVERSITY OF TEXAS	160877/159050		-\$1,884	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	111287240-7798085	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287240-7798085		-\$21	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	111287250-7859265	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	111287250-7859265		\$65,795	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	60056389	THE OHIO STATE UNIVERSITY	60056389		\$9,745	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	60059472	THE OHIO STATE UNIVERSITY	60059472		\$58,536	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00015221_SUB818_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00015221_SUB818_01		\$6,044	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	000514221-001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000514221-001		\$9,523	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	000514221-SC001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000514221-SC001		\$21,026	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15221_SUB793_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP15221_SUB793_01		\$1,898	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP21771_A1_SUB01_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP21771_A1_SUB01_01		\$21,627	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	RGF011027-A	CHILDREN'S HOSPITAL OF LOS ANGELES	RGF011027-A		-\$916	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	RGF011027-A	CHILDREN'S HOSPITAL OF LOS ANGELES	RGF011027-A		\$10,120	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP20648_SUB03_03	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	FP20648_SUB03_03		\$23,502	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	9009627-023_NATIONWIDE AMND1	OREGON HEALTH SCIENCES UNIVERSITY	9009627-023_NATIONWIDE AMND1		\$2,107	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15221_SUB857_01	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	FP15221_SUB857_01		-\$312,888	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	950080218-XX	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	950080218-XX		\$13,346	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	950080219-S14	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	950080219-S14		\$24,026	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP24927_SUB04_01	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	FP24927_SUB04_01		\$352	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP25446_SUB01_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP25446_SUB01_01		\$180	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	000518779-001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000518779-001		\$98,653	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	20104175-RSUB	CHILDREN'S HOSPITAL OF PHILADELPHIA	20104175-RSUB		\$10,758	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	PENDING	CHILDREN'S HOSPITAL OF PHILADELPHIA	PENDING		\$26,861	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	3U10CA180888-0651	OREGON HEALTH SCIENCES UNIVERSITY	3U10CA180888-0651		\$3,517	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	2U10CA180886	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886		\$1,646	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	950080220-XX	CHILDREN'S HOSPITAL OF PHILADELPHIA	950080220-XX		\$4,269	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	60070505-NCH	THE OHIO STATE UNIVERSITY	60070505-NCH		\$11,053	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	3U10CA180886-0651	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	3U10CA180886-0651		\$113,427	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	ACNS1422 / 20126538 - RSUB	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	ACNS1422 / 20126538 - RSUB		\$83,000	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	ANBL1531 INTEGRAL / 20126779	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	ANBL1531 INTEGRAL / 20126779		\$121,520	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	ANBL1531 INTEGRATED950080220-	CHILDREN'S HOSPITAL OF PHILADELPHIA ILAB	ANBL1531 INTEGRATED950080220-		\$1,055	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	2U10CA180886	CHILDREN'S HOSPITAL OF PHILADELPHIA	2U10CA180886		\$16,361	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB614_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00026529_SUB614_01		\$1,191	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15221_SUB274_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP15221_SUB274_01		\$3,937	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP15221_SUB274_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP15221_SUB274_01		\$400	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00026529_SUB92_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00026529_SUB92_01		\$58,236	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	950090219 / 20083454	CHILDREN'S HOSPITAL OF PHILADELPHIA	950090219 / 20083454		\$1,371	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	FP00027059_SUB02_01	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00027059_SUB02_01		\$13	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	NCH-GOG0237-03	THE GOG FOUNDATION, INC.	NCH-GOG0237-03		\$12,612	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	GOG/NRG - 5 - LANKES	THE GOG FOUNDATION, INC.	GOG/NRG - 5 - LANKES		\$19,737	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	2U10CA180886	PHILADELPHIA	2U10CA180886		\$41,256	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER TREATMENT RESEARCH	93.395	20125578 - RSUB	CHILDREN'S ONCOLOGY GROUP	20125578 - RSUB		\$11,919	\$954,821	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER BIOLOGY RESEARCH	93.396	5R21CA195324-02	CHILDREN'S HOSPITAL OF PHILADELPHIA	5R21CA195324-02		\$15,843	\$32,442	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER BIOLOGY RESEARCH	93.396	SUP1601	CHILDREN'S HOSPITAL OF LOS ANGELES	SUP1601		\$4,570	\$32,442	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER BIOLOGY RESEARCH	93.396	10037968-NCH	THE UNIVERSITY OF UTAH	10037968-NCH		\$2,573	\$32,442	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER BIOLOGY RESEARCH	93.396	10037968-NCH	THE UNIVERSITY OF UTAH	10037968-NCH		\$981	\$32,442	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER BIOLOGY RESEARCH	93.396	MUSC19-041-8D849	MEDICAL UNIVERSITY OF SOUTH CAROLINA	MUSC19-041-8D849		\$8,475	\$32,442	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CENTERS SUPPORT GRANTS	93.397	60069547	THE OHIO STATE UNIVERSITY	60069547		\$7,296	\$43,113	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER CENTERS SUPPORT GRANTS	93.397	60069547	THE OHIO STATE UNIVERSITY	60069547		\$35,786	\$43,113	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CENTERS SUPPORT GRANTS	93.397	60069547	THE OHIO STATE UNIVERSITY	60069547		\$31	\$43,113	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER RESEARCH MANPOWER	93.398	5K08CA201638-02				\$2	\$342,512	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER RESEARCH MANPOWER	93.398	5K08CA201638-03				\$77,390	\$342,512	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER RESEARCH MANPOWER	93.398	5K08CA201638-04				\$77,159	\$342,512	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER RESEARCH MANPOWER	93.398	5F30CA210588-03				\$21,639	\$342,512	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER RESEARCH MANPOWER	93.398	1K08CA237338-01				\$143,655	\$342,512	RESEARCH AND DEVELOPMENT	\$63,933,702
CANCER RESEARCH MANPOWER	93.398	60061624	THE OHIO STATE UNIVERSITY	60061624		\$22,667	\$342,512	RESEARCH AND DEVELOPMENT	\$63,933,702
STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATIONS HEALTH	93.421	CDC7058-0-0183-1	CHANGELAB SOLUTIONS	CDC7058-0-0183-1		\$22,794	\$22,794	RESEARCH AND DEVELOPMENT	\$63,933,702
NON-ACA/PPHF BUILDING CAPACITY OF THE PUBLIC HEALTH SYSTEM TO IMPROVE POPULATION HEALTH THROUGH NATIONAL NONPROFIT ORGANIZATIONS	93.424	CDC7046001831	CHANGELAB SOLUTIONS	CDC7046001831		\$13,479	\$13,479	RESEARCH AND DEVELOPMENT	\$63,933,702
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G1819-22-0497	OHIO CHILDRENS TRUST FUND	G1819-22-0497		\$57,879	\$691,605	RESEARCH AND DEVELOPMENT	\$63,933,702
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G1819-22-0497	OHIO CHILDRENS TRUST FUND	G1819-22-0497	\$270,895	\$486,399	\$691,605	RESEARCH AND DEVELOPMENT	\$63,933,702
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2021-22-0228	OHIO CHILDRENS TRUST FUND	G-2021-22-0228		\$36,272	\$691,605	RESEARCH AND DEVELOPMENT	\$63,933,702
COMMUNITY-BASED CHILD ABUSE PREVENTION GRANTS	93.590	G-2021-22-0228	OHIO CHILDRENS TRUST FUND	G-2021-22-0228	\$10,257	\$111,055	\$691,605	RESEARCH AND DEVELOPMENT	\$63,933,702
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	60065577	THE OHIO STATE UNIVERSITY	60065577		\$9,339	\$18,973	RESEARCH AND DEVELOPMENT	\$63,933,702
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	60072043	THE OHIO STATE UNIVERSITY	60072043		\$9,634	\$18,973	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	140609	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	140609		-\$1,203	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	60065948	THE OHIO STATE UNIVERSITY	60065948		\$41,391	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	60069606	THE OHIO STATE UNIVERSITY	60069606		\$67,800	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	60069606	THE OHIO STATE UNIVERSITY	60069606		\$65,494	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	60072687	THE OHIO STATE UNIVERSITY	60072687		\$27,606	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	60072687	THE OHIO STATE UNIVERSITY	60072687		\$39,834	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	G-2021-05-0069 / 60073392	THE OHIO STATE UNIVERSITY	G-2021-05-0069 / 60073392		\$1,140	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
MEDICAL ASSISTANCE PROGRAM	93.778	60073352	THE OHIO STATE UNIVERSITY	60073352		\$4,956	\$247,018	RESEARCH AND DEVELOPMENT	\$63,933,702
OPIOID STR	93.788	1900640	OHIO DEPARTMENT OF MENTAL HEALTH	1900640		\$9,164	\$21,604	RESEARCH AND DEVELOPMENT	\$63,933,702
OPIOID STR	93.788	1900358	OHIO DEPARTMENT OF MENTAL HEALTH	1900358		\$12,440	\$21,604	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R00HL116769				\$0	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R00HL116769-05				\$124,378	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	K08HL121182				\$0	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL127033-04 REVISED				\$70,012	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL128847-03 REVISED			\$36,907	\$85,550	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL128847-04			\$13,693	\$561,576	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K23HL127224-03				\$84,694	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K23HL127224-04				\$68,945	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01HL098228				-\$1	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL098228-09			\$70,718	\$158,970	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01HL121797				-\$2,138	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL121797-04				\$217,163	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL121797-04				\$26,415	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$34,457	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09			\$26,153	\$26,153	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$28,219	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				-\$966	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09			\$11,831	\$11,831	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09			\$41,021	\$41,021	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$25,950	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$21,330	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5T32HL098039-09				\$22,245	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01HL132801				-\$929	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-03			\$34,465	\$195,597	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-03				\$98,184	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-03				\$126,117	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-04				\$86,088	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL132801-04			\$50,347	\$220,087	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135657-02				\$181,971	\$248,985	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL135657-03				\$105,962	\$150,915	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL139796-02			\$314,647	\$860,301	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL139796-01 REVISED			\$11,388	\$37,760	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL139796-03				\$21,713	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL142685-01 REVISED				\$160,351	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	4R00HL131682-03				\$175,896	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	3R00HL131682-03S1				\$10,562	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R00HL131682-04				\$93,458	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL145032-01			\$22,997	\$649,487	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145032-02				\$55,727	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	7R01HL135103-03			\$44,102	\$257,755	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1U34HL144360-01				\$103,528	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1F31HL145962-01				\$14,630	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R03HL148368-01				\$21,797	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL144009-01A1				\$109,630	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1UG3HL148693-01				\$30,257	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	11262SUB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	11262SUB		-\$26,795	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	FP11498 A1 SUB32 01; 961749 -	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP11498 A1 SUB32 01; 961749 -		-\$4,720	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R10178028	UNIVERSITY AT BUFFALO	R10178028		-\$1,770	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1130649	UNIVERSITY AT BUFFALO	R1130649		\$176,102	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	R1177603	UNIVERSITY AT BUFFALO	R1177603		\$185,907	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	3200170321	CHILDREN'S HOSPITAL OF PHILADELPHIA	3200170321		-\$15,300	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	3200170321	CHILDREN'S HOSPITAL OF PHILADELPHIA	3200170321		\$15,300	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60054857	THE OHIO STATE UNIVERSITY	60054857		-\$33,279	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60054857	THE OHIO STATE UNIVERSITY	60054857		-\$770	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60059647	THE OHIO STATE UNIVERSITY	60059647		-\$9,318	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60059645	THE OHIO STATE UNIVERSITY	60059645		-\$66,026	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60064759	THE OHIO STATE UNIVERSITY	60064759		\$216,473	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60071089	THE OHIO STATE UNIVERSITY	60071089		\$118,039	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	3004465579	REGENTS UNIVERSITY OF MICHIGAN	3004465579		\$2,769	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	3004465579	REGENTS UNIVERSITY OF MICHIGAN	3004465579		\$21,215	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	GK000118 (CON-80000060)	YALE UNIVERSITY	GK000118 (CON-80000060)		\$88,683	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	17-028	THE UNIVERSITY OF TEXAS	17-028		\$15,373	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60061925	THE OHIO STATE UNIVERSITY	60061925		-\$492	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60061925	THE OHIO STATE UNIVERSITY	60061925		\$53,573	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	201602680-02	UC DAVIS MEDICAL CENTER	201602680-02		\$1,083	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	60061992	THE OHIO STATE UNIVERSITY	60061992		\$10,497	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	FUEL-OLE	NEW ENGLAND RESEARCH CENTER	FUEL-OLE		\$25,126	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	7000000719	BAYLOR COLLEGE OF MEDICINE	7000000719		\$36,321	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	417351G/UR FAO GR510808	UNIVERSITY OF ROCHESTER	417351G/UR FAO GR510808		\$15,820	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R41HL144143-01	LYST THERAPEUTICS, LLC	1R41HL144143-01		\$67,325	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	310969	A EINSTEIN COLLEGE OF MEDICINE	310969		\$13,245	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
CARDIOVASCULAR DISEASES RESEARCH	93.837	U24HL135691	NEW ENGLAND RESEARCH CENTER	U24HL135691		\$10,626	\$6,248,707	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	1K08HL129080-01A1				-\$4,041	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5K08HL129080-03				\$125,463	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5K08HL129080-04				\$47,940	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	R01HL087778				-\$2,902	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5R01HL087778-10				\$155,137	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	1R03HL136794-01				-\$462	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5R03HL136794-02				\$52,456	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	1K08HL138460-01				\$29,799	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5K08HL138460-02				\$91,726	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5K08HL138460-03				\$89,993	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	RHL140272A				-\$888	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5R03HL140272-02			\$21,038	\$67,111	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	1R01HL136963-01A1			\$14,798	\$34,764	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	5R01HL136963-02			\$19,727	\$360,183	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	5R00HL131682-04				\$27,651	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	1R01HL144652-01A1				\$86,508	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	000507756-001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000507756-001		\$3,500	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	109375UB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	109375UB		-\$1,782	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	60066460	THE OHIO STATE UNIVERSITY	60066460		\$50,901	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
LUNG DISEASES RESEARCH	93.838	ROUTE KEY #3201160619	CHILDREN'S PHILADELPHIA NATIONAL CUSTOMER	ROUTE KEY #3201160619		\$2,000	\$1,215,057	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R01HL119485-05				\$143,167	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	KHL127303A				\$23,933	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5K23HL127303-04				\$72,170	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5K23HL127303-05				\$89,815	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	K08HL123925				-\$1,762	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5K08HL123925-04				\$45,744	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5K08HL123925-05				\$115,921	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R21HL129019-02				-\$309	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R21HL140269-02				\$114,437	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	7R01HL131645-03				\$297,397	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R01HL131645-04				\$120,050	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1R03HL146877-01				\$48,163	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	69254-1006	NATIONAL CHILDHOOD CANCER FOUNDATION	69254-1006		-\$806	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	WU-17-224	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-17-224		-\$168	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	WU-17-102-MOD-4	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-17-102-MOD-4		\$5,885	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	WU-14-106	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-14-106		-\$8,748	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	WU-14-106	WASHINGTON UNIVERSITY	WU-14-106		-\$107,228	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	WU-15-410-MOD002	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-15-410-MOD002		\$22,400	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	WU-15-410-MOD-3	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-15-410-MOD-3		\$133,565	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	ACRI 19-001	ALL CHILDREN'S RESEARCH INSTITUTE, INC.	ACRI 19-001		\$1,640	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	ACRI 19-001	ALL CHILDREN'S RESEARCH INSTITUTE, INC.	ACRI 19-001		-\$644	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	PBMTc STUDY NO. 1507	CHILDREN'S HOSPITAL OF LOS ANGELES	PBMTc STUDY NO. 1507		\$1,270	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1U01HL143477	THE MEDICAL COLLEGE OF WISCONSIN	1U01HL143477		\$43,781	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	1U01HL143477	THE MEDICAL COLLEGE OF WISCONSIN	1U01HL143477		\$11,044	\$1,170,717	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	R01AR049722				-\$2,080	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR049722-10			\$155,370	\$393,997	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	R01AR062123				-\$684	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R21AR068040-02				\$70,113	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	P50AR070604				-\$954	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	P50AR070604				-\$1,410	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	P50AR070604				\$225	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	P50AR070604				-\$1,920	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03			\$12,144	\$75,094	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03				\$146,755	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03				\$76,080	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03				\$265,142	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03				\$240,654	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03				\$176,025	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-03				\$1,219	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$40,755	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$70,077	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$32,167	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$98,364	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$76,214	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$102,507	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$13,019	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5P50AR070604-04				\$5,308	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R21AR070509-02			\$14,567	\$60,928	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR073311-01			\$145,799	\$289,779	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR073311-02				\$208,767	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1R01AR073908-01A1				\$114,479	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$33,125	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$4,605	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$50,033	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	138708	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	138708		\$330	\$2,638,713	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01DK068158				\$151,230	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01DK095059				\$83,512	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	UM1DK100866				\$0	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5UM1DK100866-06			\$293,673	\$533,908	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5UM1DK100866-06			\$85,120	\$94,909	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5UM1DK100866-06			\$82,356	\$295,845	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5UM1DK100866-06 REVISED				\$159,960	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5UM1DK100866-06 REVISED			\$19,600	\$20,786	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R03DK109242-02 REVISED				\$22,823	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK110077-02 REVISED			\$156,002	\$156,658	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK110077-03			\$149,145	\$208,671	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK110077-04				\$52,018	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847					-\$3,589	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK102594-04				\$64,062	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK102594-05				\$98,994	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	K08DK103982				-\$2,260	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK103982-04				\$117,843	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK103982-05				\$55,587	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5F32DK115085-02				\$23,145	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5F32DK115085-03				\$33,368	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK115737-01			\$2,781	\$30,250	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK115737-02			\$6,692	\$321,591	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK114035-01A1			\$2,128	\$66,475	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK114035-02				\$263,662	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R03DK118306-01				\$60,224	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702

<i>Federal Awarding Agency/Program Title</i>	<i>Federal CFDA Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R03DK118306-02				\$42,386	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R03DK118315-01				\$67,775	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R03DK118315-02				\$39,719	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R13DK121515-01				\$10,000	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K08DK122119-01				\$92,089	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2U01DK100866-07				\$126,613	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	700000297	BAYLOR COLLEGE OF MEDICINE	700000297		-\$1,072	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	700000297	BAYLOR COLLEGE OF MEDICINE	700000297		\$38,782	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	700000297	BAYLOR COLLEGE OF MEDICINE	700000297		\$26,420	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	242081	UNIVERSITY OF SOUTH FLORIDA	242081		-\$17,036	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	253711	UNIVERSITY OF SOUTH FLORIDA	253711		\$17,597	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	253711	UNIVERSITY OF SOUTH FLORIDA	253711		\$15,674	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	330182	CHILDREN'S HOSPITAL OF PHILADELPHIA	330182		-\$13,096	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3301820718-P	CHILDREN'S HOSPITAL OF PHILADELPHIA	3301820718-P		-\$15,366	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3301820719	CHILDREN'S HOSPITAL OF PHILADELPHIA	3301820719		\$17,046	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3301820720	CHILDREN'S HOSPITAL OF PHILADELPHIA	3301820720		\$419	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	SPO 6047721	THE MEDICAL COLLEGE OF WISCONSIN	SPO 6047721	\$25,754	\$129,493	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	W001038130	THE UNIVERSITY OF IOWA	W001038130		\$0	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S00540-01	THE UNIVERSITY OF IOWA	S00540-01		\$302	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	S00540-01	THE UNIVERSITY OF IOWA	S00540-01		\$1,748	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	76752049	UNIVERSITY OF SOUTHERN CALIFORNIA	76752049		\$25,197	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	232762	UNIVERSITY OF SOUTH FLORIDA	232762		-\$295	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60058926-RINCH	THE OHIO STATE UNIVERSITY	60058926-RINCH		\$60,521	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60058926-RINCH	THE OHIO STATE UNIVERSITY	60058926-RINCH		\$523,092	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60071976	THE OHIO STATE UNIVERSITY	60071976		\$44,251	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	574238	UNIVERSITY OF PENNSYLVANIA	574238		\$1,747	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M7369	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M7369		\$24,043	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	FY18.963.003/ 2-5-M8526	UNIVERSITY OF COLORADO DENVER	FY18.963.003/ 2-5-M8526		\$508	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	IN468991 NCH	INDIANA UNIVERSITY	IN468991 NCH		\$4,497	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60069457	THE OHIO STATE UNIVERSITY	60069457		\$28,580	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	60069457	THE OHIO STATE UNIVERSITY	60069457		\$566	\$4,201,872	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	R01NS085238				-\$1,378	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702

<i>Federal Awarding Agency/Program Title</i>	<i>Federal CFDA Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS085238-05			\$79,028	\$168,805	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS085238-05				\$130,151	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R21NS101166-01				\$68,182	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	4R33NS101166-02				\$66,632	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1R01NS105986-01				\$1,017,209	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	60060485	THE OHIO STATE UNIVERSITY	60060485		-\$407	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	60060614	THE OHIO STATE UNIVERSITY	60060614		-\$69	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	0030451 (123192)	UNIVERSITY OF PITTSBURGH	0030451 (123192)		\$36,048	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC		-\$9,500	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC00	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC00		-\$255	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC		-\$29,183	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC		\$11,736	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC		\$64,081	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC		\$11,408	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9675SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9675SC		\$24,698	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1600891	UNIVERSITY OF MARYLAND	1600891		\$8,535	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	137754	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	137754		\$523	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	416688	UNIVERSITY OF ROCHESTER	416688		-\$23,686	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	417090/UR FOA GR510660	UNIVERSITY OF ROCHESTER	417090/UR FOA GR510660		-\$907	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	417412/URGAO; GR510660	UNIVERSITY OF ROCHESTER	417412/URGAO; GR510660		\$974	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	417215/UR FOA GR510660	UNIVERSITY OF ROCHESTER	417215/UR FOA GR510660		\$24,559	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 154465	UNIVERSITY OF VIRGINIA	GB10094 154465		-\$76,927	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 157949	UNIVERSITY OF VIRGINIA	GB10094 157949		\$105,569	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 157949	UNIVERSITY OF VIRGINIA	GB10094 157949		\$580	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 157949	UNIVERSITY OF VIRGINIA	GB10094 157949		\$48,746	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GB10094 PO2167933	UNIVERSITY OF VIRGINIA	GB10094 PO2167933		\$8,443	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	16-8475	UNIVERSITY OF WISCONSIN AT MADISON	16-8475		\$1,500	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	9688SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	9688SC		-\$1,746	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	CNVA00050115 (132762-6)	UNIVERSITY OF PITTSBURGH	CNVA00050115 (132762-6)		\$1,050	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NN107 - FX-LEARN	MASSACHUSETTS GENERAL HOSPITAL	NN107 - FX-LEARN		\$7,450	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	10497SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	10497SC		\$1,021	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	10497SC	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	10497SC		\$1,636	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GO12275 157197	UNIVERSITY OF VIRGINIA	GO12275 157197		-\$2,300	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	GO12275 157197	UNIVERSITY OF VIRGINIA	GO12275 157197		\$5,800	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	30003963-09	CHILDREN'S NATIONAL MEDICAL CENTER	30003963-09		-\$32,457	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	60066420	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60066420		\$45,005	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	60071521	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60071521		\$10,592	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	210305-0819-02	THE JACKSON LABORATORY	210305-0819-02		\$105,004	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	210305-0819-02	THE JACKSON LABORATORY	210305-0819-02		\$28,920	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	S-001035	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	S-001035		\$44,872	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	S-001035	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	S-001035		\$38,400	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	110265C	UNIVERSITY OF CALIFORNIA, SAN DIEGO	110265C		\$10,111	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	110265C	UNIVERSITY OF CALIFORNIA, SAN DIEGO	110265C		\$4,967	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	432107-19D50	VIRGINIA POLYTECHNIC INSTITUTE	432107-19D50		\$44,201	\$1,968,593	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5K08AI108792-04				-\$334	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5K08AI108792-05				\$138,772	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01AI093848-06				\$233,516	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI114581-01				\$60,493	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI114581-05				\$261,889	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI126890-03			\$300,531	\$419,618	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI126890-04				\$159,780	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	U01AI131313				-\$256	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01AI131313-03			\$43,200	\$160,838	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01AI131313-04				\$43,210	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI124029-02				-\$314	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI124029-03				\$400,806	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI124029-04				\$77,019	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04				\$14,109	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05			\$67,183	\$67,183	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04				\$40,354	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04				-\$835	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04			\$57,841	\$57,841	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04				-\$3,261	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04			\$44,228	\$44,228	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-04				\$196,050	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	3P01AI112524-04S1				\$12,645	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05				\$91,448	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05			\$140,986	\$141,354	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05				\$215,629	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05			\$102,994	\$102,994	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05				\$137,478	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05			\$141,568	\$141,568	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05				\$134,175	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5P01AI112524-05				\$48,313	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	R21AI122228				-\$1,317	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RAI101138C				\$429,268	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	R21AI120013				-\$206	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI125489-01A1				-\$2,456	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI125489-02			\$38,462	\$239,969	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI125489-03				\$150,279	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	UA1131386A				-\$1,785	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01AI131386-02			\$263,129	\$396,942	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01AI131386-02 REVISED			\$179,081	\$242,411	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5U01AI131386-03			\$138,736	\$195,613	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI134848-01A1			\$45,187	\$56,527	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI134848-02			\$45,594	\$449,443	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI137912-01				\$5,345	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R21AI137912-02				\$144,841	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI137567-01			\$47,016	\$78,727	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI137567-02				\$11,022	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	2R01AI096882-06			\$171,381	\$318,012	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI096882-07				\$211,173	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI139511-01A1			\$134,980	\$277,109	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI139511-02			\$23,057	\$110,287	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1F30AI143060-01				\$38,292	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7R01AI116917-05			\$5,417	\$246,542	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5R01AI116917-06			\$10,503	\$308,978	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI142885-01				\$95,781	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI140001-01A1 REVISED				\$134,729	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI139519-01A1				\$124,598	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R21AI142433-01A1 REVISED				\$36,356	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1R01AI143740-01				\$51,803	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	96338 4	BIOFIRE DIAGNOSTICS, INC.	96338 4		\$22,301	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60045775	THE OHIO STATE UNIVERSITY	60045775		-\$1,303	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	S00167-01	THE UNIVERSITY OF IOWA	S00167-01		-\$46	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	S00167-01	THE UNIVERSITY OF IOWA	S00167-01		\$6,835	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	S00167-01	THE UNIVERSITY OF IOWA	S00167-01		\$9,460	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	PRO 00045657	DUKE UNIVERSITY	PRO 00045657		\$618	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5 R01 AI 120655 -02	THE MEDICAL COLLEGE OF WISCONSIN	5 R01 AI 120655 -02		-\$1,934	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	MCW PO REQ	THE MEDICAL COLLEGE OF WISCONSIN	MCW PO REQ		\$84,519	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	WU-18-112-MOD-2	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-18-112-MOD-2		\$3,664	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1500730	UNIVERSITY OF MARYLAND	60045730		\$5,776	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	1500730 / 2550	UNIVERSITY OF MARYLAND	1500730 / 2550		\$23,030	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60064946	THE OHIO STATE UNIVERSITY	60064946		\$39,690	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	VUMC 59103	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC 59103		-\$1,745	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	VUMC59103	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC59103		\$56,156	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	VUMC59103	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC59103		\$4,151	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	WU-18-124	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-18-124		\$375	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	WU-18-139	WASHINGTON UNIVERSITY IN ST. LOUIS	WU-18-139		\$586	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	FY18.777.001	UNIVERSITY OF COLORADO DENVER	FY18.777.001		\$20,672	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	FY18.777.001	UNIVERSITY OF COLORADO DENVER	FY18.777.001		\$6,550	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AWD7773224-GR205827	GEORGETOWN UNIVERSITY	AWD7773224-GR205827		\$15,373	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	5936-NCH-DHHS-4911	UNIVERSITY OF PENNSYLVANIA STATE	5936-NCH-DHHS-4911		\$12,189	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$117,577	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	RC106925RINCHSUPP	MICHIGAN STATE UNIVERSITY	RC106925RINCHSUPP		\$8,954	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60069338	THE OHIO STATE UNIVERSITY	60069338		\$17,959	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	210310-0320-11	THE JACKSON LABORATORY	210310-0320-11		\$20,113	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	7R01AI134911	CARNEGIE MELLON UNIVERSITY	7R01AI134911		\$10,961	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60071577	THE OHIO STATE UNIVERSITY	60071577		\$19,287	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	60062781	THE OHIO STATE UNIVERSITY	60062781		\$17,082	\$8,689,780	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R01GM094203				-\$13,536	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R01GM103612				\$121	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R01GM103612				-\$1	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM113236-04				\$217,601	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-02				\$25,757	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-02				\$43,864	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-02				\$32,469	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-02			\$32,004	\$32,004	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-03				\$83,397	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-03				\$99,496	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-03				\$52,716	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM123482-03			\$17,520	\$17,520	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	1K08GM124499-01A1				\$82,880	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K08GM124499-02				\$43,402	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	60049375	THE OHIO STATE UNIVERSITY	60049375		\$7,724	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	WU-16-71-MOD-4	WASHINGTON UNIVERSITY	WU-16-71-MOD-4		\$15,165	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	112157030-7768632	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	112157030-7768632		\$876	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	112157040-7833490	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	112157040-7833490		\$60,649	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	112157050-7892875	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	112157050-7892875		\$34,888	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	430-40-18A	IOWA STATE UNIVERSITY	430-40-18A		\$11,113	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	SCN-1006683	IOWA STATE UNIVERSITY	SCN-1006683		\$125,096	\$973,201	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD076885			-\$9,184	-\$7,050	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD076885-05 REVISED			\$131,381	\$136,585	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD083170-04				-\$10,783	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD083170-05				\$219,535	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3UG1HD083170-0551				\$878	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD068278-08				\$69,434	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5UG1HD068278-09				\$227,028	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R25HD086885-03				\$10,930	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R25HD086885-04				\$98,184	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R03HD084927				\$28,317	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R21HD086451-02				\$50,639	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD088033			\$236	\$522	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD088033-03			\$48,778	\$303,122	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD088033-04				\$20,692	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD084628-04			\$33,599	\$37,665	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5K01HD083459-04				\$83,524	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5K01HD083459-05				\$37,013	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01HD081120				-\$5,422	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD081120-04			\$19,243	\$179,683	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD081120-05			\$12,511	\$159,978	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R21HD085122				\$11,323	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R21HD089526-02			\$4,845	\$23,078	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD093706-01A1			\$35,067	\$237,969	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD093706-02				\$121,887	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD091347-01A1 REVISED			\$421,216	\$489,927	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD091347-02				\$2,653	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	2R01HD074594-05A1				\$175,011	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD074594-06				\$97,644	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1K99HD093814-01A1				\$55,989	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5K99HD093814-02				\$26,413	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD098176-01			\$14,103	\$35,531	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD095976-01A1				\$114,178	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R03HD099241-01				\$18,091	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60068598	THE OHIO STATE UNIVERSITY	60068598		\$129	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60049375	THE OHIO STATE UNIVERSITY	60049375		\$69,938	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60064602-NCH	OSU COLLEGE OF MEDICINE	60064602-NCH		\$755	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60069774-NCH	OSU COLLEGE OF MEDICINE	60069774-NCH		\$4,271	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60030851	THE OHIO STATE UNIVERSITY	60030851		\$0	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC53266	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC53266		\$8,608	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC53266	VANDERBILT UNIVERSITY MEDICAL CENTER	VUMC53266		\$14,625	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	114375UB	SEATTLE CHILDREN'S RESEARCH INSTITUTE	114375UB		\$23,218	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	WA00589299/RFS2016045	UNIVERSITY OF MASSACHUSETTS, WORCESTER	WA00589299/RFS2016045		\$0	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60040175	THE OHIO STATE UNIVERSITY	60040175		\$1,405	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60040175	THE OHIO STATE UNIVERSITY	60040175		\$4,456	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	212456	RTI INTERNATIONAL	212456		-\$262,074	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	212456	RTI INTERNATIONAL	212456		\$327,639	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	216392	RTI INTERNATIONAL	216392		\$199,877	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		-\$36,927	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		-\$14,452	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		-\$38,265	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		\$44,243	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		\$1,009	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		\$2,743	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		\$3,662	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		\$8,098	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	10035609-NWCH	THE UNIVERSITY OF UTAH	10035609-NWCH		\$88	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3004685877	REGENTS UNIVERSITY OF MICHIGAN	3004685877		\$140,596	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3004685877	REGENTS UNIVERSITY OF MICHIGAN	3004685877		\$17	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60061164	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60061164		\$6,947	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60061164	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60061164		\$34,129	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1644 G VAO41	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	1644 G VAO41		\$20	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60067323	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067323		\$6,619	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	60067323	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067323		\$7,163	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R70507-3214	EASTERN MICHIGAN UNIVERSITY	R70507-3214		\$36,238	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R70507-3214	EASTERN MICHIGAN UNIVERSITY	R70507-3214		\$17,671	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OSP2018144	UNIVERSITY OF MASS, WORCESTER	OSP2018144		\$44,418	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	OSP2018144	UNIVERSITY OF MASS, WORCESTER	OSP2018144		\$43,782	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	30004942-09	CHILDREN'S NATIONAL MEDICAL CENTER	30004942-09		\$47,329	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	30004942-09	CHILDREN'S NATIONAL MEDICAL CENTER	30004942-09		\$22,638	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	NCH31227-01	LA BIOMEDICAL RESEARCH INST	NCH31227-01		\$627	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	901558-NATIONWIDE	ANN & ROBERT H. LURIE CHILDREN'S	901558-NATIONWIDE		\$16,461	\$3,837,869	RESEARCH AND DEVELOPMENT	\$63,933,702
AGING RESEARCH	93.866	7R01AG050581-03				\$0	\$261,951	RESEARCH AND DEVELOPMENT	\$63,933,702
AGING RESEARCH	93.866	5R01AG050581-04				\$130,011	\$261,951	RESEARCH AND DEVELOPMENT	\$63,933,702
AGING RESEARCH	93.866	5R01AG050581-05				\$94,973	\$261,951	RESEARCH AND DEVELOPMENT	\$63,933,702

Federal Awarding Agency/Program Title	Federal CFDA Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	60067217	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067217		\$16,635	\$261,951	RESEARCH AND DEVELOPMENT	\$63,933,702
AGING RESEARCH	93.866	60067217	THE OHIO STATE UNIVERSITY MEDICAL CENTER	60067217		\$20,332	\$261,951	RESEARCH AND DEVELOPMENT	\$63,933,702
VISION RESEARCH	93.867	SITE ID 26	JAEB CENTER FOR HEALTH CHILDREN'S HOSPITAL OF PHILADELPHIA	SITE ID 26		-\$893	-\$1,135	RESEARCH AND DEVELOPMENT	\$63,933,702
VISION RESEARCH	93.867	3209850817	THE OHIO STATE UNIVERSITY	3209850817		\$0	-\$1,135	RESEARCH AND DEVELOPMENT	\$63,933,702
VISION RESEARCH	93.867	60053163	THE OHIO STATE UNIVERSITY	60053163		-\$242	-\$1,135	RESEARCH AND DEVELOPMENT	\$63,933,702
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0319	OHIO DEPARTMENT OF HEALTH	02560511MH0319		\$471,681	\$615,989	N/A	\$0
MATERNAL, INFANT AND EARLY CHILDHOOD HOME VISITING GRANT	93.870	02560511MH0420	OHIO DEPARTMENT OF HEALTH UNIVERSITY HOSPITALS CLEVELAND	02560511MH0420		\$144,308	\$615,989	N/A	\$0
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM RURAL HEALTH CARE SERVICES OUTREACH, RURAL HEALTH NETWORK DEVELOPMENT AND SMALL HEALTH CARE PROVIDER QUALITY IMPROVEMENT	93.889	U3REP190615-01-00	MEDICAL CENTER	U3REP190615-01-00		\$52,960	\$52,960	RESEARCH AND DEVELOPMENT	\$63,933,702
HIV EMERGENCY RELIEF PROJECT GRANTS	93.912	UT18522	OHIO UNIVERSITY	UT18522		\$0	\$0	RESEARCH AND DEVELOPMENT	\$63,933,702
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$231,887	\$495,710	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$126,485	\$495,710	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$43,533	\$495,710	N/A	\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$0	\$495,710	RESEARCH AND DEVELOPMENT	\$63,933,702
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$60,214	\$495,710	RESEARCH AND DEVELOPMENT	\$63,933,702
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$25,924	\$495,710	RESEARCH AND DEVELOPMENT	\$63,933,702
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	FACES PART A	THE CITY OF COLUMBUS	FACES PART A		\$7,667	\$495,710	RESEARCH AND DEVELOPMENT	\$63,933,702
HIV CARE FORMULA GRANTS	93.917	02560511QI0218	OHIO DEPARTMENT OF HEALTH	02560511QI0218		\$26,873	\$26,873	N/A	\$0
HIV CARE FORMULA GRANTS	93.917	02560511QI0117	OHIO DEPARTMENT OF HEALTH	02560511QI0117		\$0	\$26,873	RESEARCH AND DEVELOPMENT	\$63,933,702
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	5 H76HA247360800				\$275,368	\$464,644	N/A	\$0
GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE	93.918	2 H76HA247360700				\$189,276	\$464,644	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	1900113	OHIO DEPARTMENT OF MENTAL HEALTH	1900113		-\$2,195	\$92,987	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	1900113	OHIO DEPARTMENT OF MENTAL HEALTH	1900113	\$74,434	\$74,434	\$92,987	RESEARCH AND DEVELOPMENT	\$63,933,702
BLOCK GRANTS FOR PREVENTION AND TREATMENT OF SUBSTANCE ABUSE	93.959	2000144	OHIO DEPARTMENT OF MENTAL HEALTH	2000144	\$20,748	\$20,748	\$92,987	RESEARCH AND DEVELOPMENT	\$63,933,702
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	000406268-11	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000406268-11		\$1,050	\$1,270	RESEARCH AND DEVELOPMENT	\$63,933,702
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	000406190-016	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000406190-016		\$220	\$1,270	RESEARCH AND DEVELOPMENT	\$63,933,702
RETROSPECTIVE ASSESSMENT OF JU CPSCDPS CPSC-N-14-0010 NEISS	93.RD	S270151-12	EASTERN VIRGINIA MEDICAL SCHOOL	S270151-12		\$2,568	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
CPSCDPS CPSC-N-14-0010 NEISS	93.RD	CPSC-N-14-0010				-\$81,890	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
CPSCDPS CPSC-N-14-0010 NEISS	93.RD	CPSC-N-14-0010				\$81,890	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
CPSCDPS CPSC-N-14-0010 NEISS	93.RD	CPSC-N-14-0010				\$124,182	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
NEISS	93.RD	CPS-21131-19-0023				\$70,416	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
HRSA T05-TO SUPPORT THE ACHDNC	93.RD	A030564	DUKE UNIVERSITY	A030564		\$148,816	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
HRSA TASK ORDER (TO)3	93.RD	2037580	DUKE UNIVERSITY	2037580		\$0	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
EMPOWERCARE: PH 2 MCHB PRIZE	93.RD	4580.004	CAPITAL CONSULTING CORPORATION	4580.004		\$6,745	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
SPEAKHEALTH: PH 2 MCHB PRIZE	93.RD	44580.003	CAPITAL CONSULTING CORPORATION	44580.003		\$17,604	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
T06 HRSA	93.RD	A030693	DUKE UNIVERSITY	A030693		\$87,865	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001				\$972,554	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001				\$112,828	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
BCR TASK ORDER #1 TASK A-BPC	93.RD	HHSN26100001 P00006				\$856,224	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
BCR TASK ORDER #1 TASK B-CBA	93.RD	HHSN26100001 P00006				-\$7,440	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
NCI BCR TO#2 BASE	93.RD	HHSN26100002				\$363,224	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
NCI BCR TO#2 TRAVEL	93.RD	HHSN26100002				-\$5,262	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
NCI BCR TO#2 TRAVEL	93.RD	HHSN26100002				\$9,206	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
NCI BCR TO#2 INT SHIP	93.RD	HHSN26100002				\$4,570	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
19X092Q2-LEIDOS-PERLMAN STUDY	93.RD	19X092Q2	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q2		\$4,862	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
LBR 11XS089	93.RD	11XS089	LEIDOS BIOMEDICAL RESEARCH, INC	11XS089		\$253,803	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702

<i>Federal Awarding Agency/Program Title</i>	<i>Federal CFDA Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
12XS383 HTMCP DATA COLLECTION	93.RD	12XS383	LEIDOS BIOMEDICAL RESEARCH, INC	12XS383		\$109,839	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>PEDIATRIC NCI - MATCH APEC1621</i>	93.RD	17X033Q2	LEIDOS BIOMEDICAL RESEARCH, INC	17X033Q2		\$960,173	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
17X033 TO: Q3 BPU ETCTN NCLN	93.RD	17X033	LEIDOS BIOMEDICAL RESEARCH, INC	17X033		\$25,500	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
19X092Q1-LEIDOS-LOH STUDY	93.RD	19X092Q1	LEIDOS BIOMEDICAL RESEARCH, INC	19X092Q1		\$5,140	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>PEDIATRIC NCI-MATCH</i>	93.RD	17X033Q1	LEIDOS BIOMEDICAL RESEARCH, INC	17X033Q1		-\$14,294	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>NCI BCR TASK ORDER #3</i>	93.RD	HHSN26100003				-\$5,874	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>BCR TASK ORDER #4</i>	93.RD	HHSN26100004				\$655,081	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>NCI BCR TASK ORDER #3</i>	93.RD	HHSN26100003				\$58,199	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>TO5: NUCLEIC ACID EXTRACTIONS</i>	93.RD	HHSN261201700015I				\$92,005	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>A TARGETED APPROACH TO A SAFER</i>	93.RD	RNG002833-BUDG03 SUB NCH MOD2	KFHPW FORMERLY GROUP HEALTH RI UNIVERSITY OF ALABAMA AT BIRMINGHAM	RNG002833-BUDG03 SUB NCH MOD2		\$427,352	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>OPTION 1</i>	93.RD	00406291-SC016	VANDERBILT UNIVERSITY MEDICAL CENTER	00406291-SC016		-\$8,551	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>EPIC</i>	93.RD	VUMC63638	CHILDREN'S HOSPITAL OF PHILADELPHIA	VUMC63638		\$21,150	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>ADENOVIRUS - OPTION 1</i>	93.RD	FP00020404-SUB01-02	CHILDREN'S HOSPITAL OF PHILADELPHIA	FP00020404-SUB01-02		\$9,309	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>ADENOVIRUS STEM CELL</i>	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621		\$14,775	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>ADENOVIRUS - OPTION 2</i>	93.RD	7300250621	CHILDREN'S HOSPITAL OF PHILADELPHIA	7300250621		\$63,856	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>ORAL VALGANCICLOVIR</i>	93.RD	000509729-001	UNIVERSITY OF ALABAMA AT BIRMINGHAM	000509729-001		\$2,074	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
<i>PEDIATRIC TRIALS NETWORK - TAS</i>	93.RD	6347 FUROSEMIDE	DUKE UNIVERSITY	6347 FUROSEMIDE		\$490	\$5,438,989	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES						<u>\$7,185,113</u>	<u>\$61,944,909</u>		
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT									
USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS	98.001	USAID AID-OAA-A-14-00017				\$5,079	\$5,079	RESEARCH AND DEVELOPMENT	\$63,933,702
TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT							<u>\$5,079</u>		
TOTAL EXPENDITURE OF FEDERAL AWARDS									
						<u>\$7,818,238</u>	<u>\$66,517,360</u>		

Please Note:

Italicized award lines indicate pass-through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.

Nationwide Children's Hospital, Inc. and Subsidiaries

Notes to the Schedule of Expenditures of Federal Awards

December 31, 2019

1. Significant Accounting Policies Used in Preparing the SEFA

Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Nationwide Children's Hospital, Inc. and Subsidiaries under programs of the federal government for the year ended December 31, 2019. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance).

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Indirect Cost Rate: Nationwide Children's Hospital, Inc. and Subsidiaries did not use the 10% de minimis indirect cost rate allowed by the Uniform Guidance.

2. 10% De Minimis Cost Rate

The auditee did not use the de minimis cost rate.

Compliance and Internal Controls



Ernst & Young LLP
Suite 200
800 Yard Street
Grandview Heights, OH 43212

Tel: +1 614 224 5678
Fax: +1 614 232 7939
ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with *Government Auditing Standards*

Senior Management and Board of Directors
Nationwide Children's Hospital, Inc.

We have audited, in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Nationwide Children's Hospital, Inc. and Subsidiaries, which comprise the consolidated balance sheet as of December 31, 2019, and the related consolidated statement of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated April 23, 2020.

Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control. Accordingly, we do not express an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. *A material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. *A significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Nationwide Children’s Hospital, Inc. and Subsidiaries’ financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

April 23, 2020



Ernst & Young LLP
Suite 200
800 Yard Street
Grandview Heights, OH 43212

Tel: +1 614 224 5678
Fax: +1 614 232 7939
ey.com

Report of Independent Auditors on Compliance for the Major Federal Program and Report on Internal Control over Compliance Required by the Uniform Guidance

Senior Management and Board of Directors
Nationwide Children's Hospital, Inc.

Report on Compliance for the Major Federal Program

We have audited Nationwide Children's Hospital, Inc. and Subsidiaries' compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on Nationwide Children's Hospital, Inc. and Subsidiaries' major federal program for the year ended December 31, 2019. Nationwide Children's Hospital, Inc. and Subsidiaries' major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for Nationwide Children's Hospital, Inc. and Subsidiaries' major federal program based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Nationwide Children's Hospital, Inc. and Subsidiaries' compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for the major federal program. However, our audit does not provide a legal determination of Nationwide Children's Hospital, Inc. and Subsidiaries' compliance.

Opinion on the Major Federal Program

In our opinion, Nationwide Children's Hospital, Inc. and Subsidiaries complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on its major federal programs for the year ended December 31, 2019.

Report on Internal Control Over Compliance

Management of Nationwide Children's Hospital, Inc. and Subsidiaries is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over compliance with the types of requirements that could have a direct and material effect on the major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for the major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Nationwide Children's Hospital, Inc. and Subsidiaries' internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.



The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

June 12, 2020

Nationwide Children's Hospital, Inc. and Subsidiaries

Schedule of Findings and Questioned Costs

Year Ended December 31, 2019

Section I – Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified?

 yes X **no**

Significant deficiency(ies) identified?

 yes X **none reported**

Noncompliance material to financial statements noted?

 yes X **no**

Federal Awards

Internal control over major federal program:

Material weakness(es) identified?

 Yes X **no**

Significant deficiency(ies) identified?

 Yes X **none reported**

Type of auditor's report issued on compliance for major federal program:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?

 yes X **no**

Nationwide Children’s Hospital, Inc. and Subsidiaries
Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor’s Results (continued)

Identification of major federal program:

<u>CFDA numbers</u>	<u>Name of federal program or cluster</u>
Various	Research and Development Cluster
Dollar threshold used to distinguish between Type A and Type B programs:	<u>\$1,995,520</u>
Auditee qualified as low-risk auditee?	<u> X </u> yes <u> </u> no

Section II – Financial Statement Findings

No matters were reported.

Section III – Federal Award Findings and Questioned Costs

No matters were reported.

About EY

EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. For more information about our organization, please visit ey.com.

© 2020 Ernst & Young LLP.
All Rights Reserved.

ey.com